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1 Summary 
SUMMARY 
 Proteolysis by viral enzymes plays a fundamental role in the viral life cycle, a fact that 
makes these proteases an attractive target for the antiviral therapy. Infections for which specific 
antiviral therapeutics are still needed include those of the human immunodeficiency virus (HIV) 
(Piacenti et al., 2006), hepatitis C virus (Lamarre et al., 2003), West Nile virus (WNV), tick-
borne encephalitis virus (TBEV) (Mansfield et al., 2009) and, as a prominent representative of 
the family of animal pathogens, the foot-and-mouth disease virus (FMDV) (Grubman and Baxt, 
2004). However, the development of such an inhibitor is difficult, as viral proteolysis is a highly 
complex process. Cleavage sites are often insufficiently defined and the development of 
resistance to inhibitors due to the error prone nature of the viral polymerase is an enduring 
problem. To overcome these obstacles, we set out to develop TBEV based systems, both 
biochemical and cell-based, which allow us to examine the properties of viral proteases in 
general, and of the TBEV protease in particular. TBEV causes the tick-borne encephalitis 
(TBE), a potentially lethal neurological disease of humans (Gritsun et al., 2003; Mansfield et al., 
2009). It belongs to the family of Flaviviridae and comprises a single positive-strand RNA 
genome, which is translated into one polyprotein. Subsequent processing by cellular proteases 
together with the viral NS2B/3 protease (NS2B/3pro) yields the mature proteins.  
 In order to set up a cell based assay that allows us to investigate various viral 
proteases, we modified the genome of TBEV in such a way that the production of infectious 
virions became dependent on the activity of a heterologous protease. To this end, the 
NS2B/3pro capsid cleavage site in the C-terminal region of TBEV was replaced by an optimised 
cleavage site for the FMDV 3C protease (3Cpro). Infectivity of this non-viable mutant could be 
regained by expression of the 3Cpro either from the same TBEV genome in cis or from a 
replicon in trans. To test the genetic stability of both systems, various TBEV mutants were 
passaged in the absence of an active 3Cpro. This led to the appearance of three revertants only 
in the mono-cistronic system, indicating that the trans-complementation system is more stable. 
In all three mutants, a NS2B/3pro cleavage motif RR*C was introduced at an identical location, 
giving rise to protein C with a C-terminal extension of 14 amino acids. A comparison of the 
revertants reveals that the more hydrophobic the extension of protein C, the lower the rate of 
early RNA synthesis in general and the later the onset of early RNA replication and/or 
unpackaging in particular. Furthermore, our results show a need of positive charges at the C-
terminus of protein C for efficient budding of the nucleocapsid, thereby highlighting the role of 
protein C as a multifunctional protein.  
 We established a system, in which a heterologous protease can recognise its 
corresponding cleavage motif in the C-terminal region of protein C and consequently allows the 
production of infectious TBEV particles. Addition of protease inhibitors to the trans-
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complementation system should allow protease mutants to be detected that are resistant to the 
inhibitor. Thus, this system can be used to further illuminate the relation between inhibitors and 
protease resistance. 
 In order to investigate the biochemical and structural properties of the NS2B/3pro we 
constructed a modular protein consisting of the protease domain of NS3 and the core-domain 
of cofactor NS2B. The protease was expressed in E.coli and purified to homogeneity via affinity 
and size exclusion chromatography. 
 The modular protease NS2B/3pro was used in a TBEV based trans-cleavage assay for 
biochemical characterisation. After eliminating unwanted autocleavage by site directed 
mutagenesis, thereby improving the activity of the protease, reaction conditions were optimised 
to allow proteolytic cleavage of in vitro translated C-prM structural precursor protein. Efficiency 
and specificity of the NS2B/3pro were enhanced by providing canine pancreatic microsomal 
membranes; unwanted signal peptidase I cleavage was prevented by lengthening the h-region 
of the signal peptide. In order to establish a system which allows us to find suitable substrates 
for the above described cell based system, we substituted the NS2B/3pro cleavage site at the C-
prM junction with a one for the HIV-1 protease (HIV-1pro). This mutant was no longer processed 
by the NS2B/3pro; instead it was recognised by the HIV-1pro which was also expressed in E.coli. 
Again, cleavage was efficient and specific in the presence of microsomal membranes. Thus, 
with this system we are able to mimic in vitro the cleavage of NS2B/3pro and HIV-1pro in vivo. 
This assay will facilitate the search for suitable substrates for the above described cell based 
assay and should enable future studies of proteolysis requirements of various proteases, even 
those that require higher biosafety level handling, in a safe system. 
 Finally, an inactivated form of the NS2B/3pro (NS2B/3pro S135A) was used in 
crystallisation experiments for structural characterisation. Crystallisation proved to be difficult, 
most probably because of the flexibility of the linker between NS3 and NS2B. As a result, 
crystallisation was only successful when we fused the protease to the maltose binding protein 
(MBP) and crystallised it in the presence of maltose as a stabilising agent. We determined 
conditions which allow a reproducible crystallisation of the MBP-NS2B/3 S135A fusion protein. 
The obtained crystals were too small and fragile for X-ray analysis, but provide a good basis for 
further optimisation.  
 Taken together, the results of this thesis extend the understanding of basic molecular 
mechanisms of the TBEV and cleavage requirements of the proteases of TBEV, FMDV and 
HIV. The assays allow the study of various aspects of viral pathogenesis and development of 
resistance to inhibitors. Thus, they provide the basis for the analysis of structure function 
relationships of viral proteases and should therefore facilitate future drug design.  
 
 
  
3 Zusammenfassung 
ZUSAMMENFASSUNG 
 Proteolyse durch virale Enzyme spielt eine fundamentale Rolle im viralen Lebenszyklus. 
Das macht virale Proteasen zu einem wichtigen Ansatzpunkt für die antivirale Therapie. Zu den 
Infektionen, für deren Behandlung immer noch Medikamente benötigt werden, gehören jene die 
durch das Humane Immundefizienz Virus (HIV, Piacenti et al., 2006), das Hepatitis C Virus 
(Lamarre et al., 2003), das West Nil Virus (WNV), sowie das Frühsommer-Meningoenzephalitis 
Virus (FSME) verursacht werden. Dasselbe gilt für einen bekannten Vertreter der 
Tierpathogene, das Maul- und Klauenseuchevirus (MKSV) (Grubman und Baxt, 2004).  
 Die Entwicklung solcher Inhibitoren gestaltet sich allerdings schwierig, da virale 
Proteolyse ein komplexer Vorgang ist. Spaltstellen sind oft ungenügend definiert; weiters ist 
das Entstehen von Resistenzen, ausgelöst durch das Fehlen eines Korrekturlesemechanismus 
der viralen Polymerase, ein großes Problem. Um diese Probleme zu beheben, haben wir 
biochemische und zellbasierte Systeme auf Grundlage des FSME Virus entwickelt, die es 
ermöglichen, virale Proteasen im allgemeinen, und die Protease des FSME Virus im speziellen, 
zu untersuchen. Das FSME Virus ist ein humanpathogenes Virus aus der Familie der 
Flaviviridae. Vom einzel- und (+)strängigen RNA Genom wird ein Vorläuferpolyprotein 
synthetisiert, das ko- und post-translational von der viralen NS2B/3 Protease (NS2B/3pro) in 
seine funktionellen Einzelproteine zerlegt wird.  
 Um ein System zu etablieren, das uns erlaubt unterschiedliche Proteasen zu 
untersuchen, war es notwendig, das Genom des FSME-Virus so zu verändern, dass die 
Entstehung infektiöser Partikel von der Aktivität einer heterologen Protease abhängt. Zu 
diesem Zweck haben wir die ursprüngliche Erkennungssequenz der FSME Protease 
(NS2B/3pro) durch eine Spaltstelle der MKSV Protease (3Cpro) ersetzt. Diese Mutante war erst 
wieder infektiös, wenn die korrespondierende Protease in cis oder in trans verfügbar war. 
 Um die genetische Stabilität der beiden Systeme zu testen, wurden unterschiedliche 
FSME Mutanten in der Abwesenheit einer aktiven 3Cpro passagiert. Das führte zum Entstehen 
von drei Revertanten im monocistronischen System, während sich das trans System als das 
stabilere erwies. In allen drei Mutanten entstand die NS2B/3pro Spaltstelle RR*C an derselben 
Position des Genoms. Dies führte zu einer Verlängerung des Kapsidproteins um 14 
Aminosäuren. Eine Analyse der Eigenschaften der Revertanten zeigte, dass eine 
hydrophobere Verlängerung des Kapsidproteins zu einer verspäteten und verringerten RNA 
Synthese führt. Effizientes Budding des Nukleokapsid ist nur möglich, wenn sich am C-
terminalen Ende des Kapsidproteins positiv geladene Aminosäuren befinden. Diese Ergebnisse 
implizieren, dass das Kapsidprotein für eine Vielzahl viraler Prozesse von Bedeutung ist.  
 Wir konnten also ein System etablieren, in dem eine heterologe Protease ihre 
korrespondierende Spaltstelle in der C-terminalen Region des Kapsidproteins erkennt und so 
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die Produktion infektiöser Virionen erlaubt. Die Anwesenheit eines Inhibitors der heterologen 
Protease provoziert das Entstehen von Mutanten, die resistent gegen den Inhibitor sind. Eine 
Analyse der Revertanten kann dazu beitragen, die Wechselbeziehung zwischen Inhibitor und 
Resistenzentstehung aufzuklären. 
 Um die biochemischen und strukturellen Eigenschaften der NS2B/3pro untersuchen zu 
können, haben wir eine modulare Protease, bestehend aus der Gensequenz der 
Proteasedomaine des NS3 Proteins verknüpft mit jener der Kernregion des Kofaktors NS2B, 
hergestellt. Diese wurde in E.coli exprimiert und via Affinitätschromatographie und Gelfiltration 
aufgereinigt. Die aktive Protease wurde, nachdem wir eine unerwünschte Selbstspaltung 
eliminieren konnten, zur Etablierung eines in vitro Assays zur biochemischen Charakterisierung 
der Protease verwendet. Das Substrat, C-prM, wurde in vitro translatiert, die 
Reaktionsbedingungen für die proteolytische Prozessierung durch die Protease optimiert. 
Effizienz und Spezifität der NS2B/3 konnten durch pankreatische mikrosomale Membranen 
weiter erhöht werden. Die damit einhergehende, unerwünschte Prozessierung durch die 
Signalpeptidase I konnten wir durch eine Verlängerung der h-region des Signalpeptids 
hemmen. Eine C-prM Mutante mit einer Erkennungssequenz für die HIV-1 Protease anstelle 
jener für die NS2B/3pro, wurde verwendet, um die biochemischen Eigenschaften der HIV-1 
Protease zu untersuchen, die ebenfalls in E.coli exprimiert wurde. Dieser Assay bietet die 
Möglichkeit, geeignete Substrate für den zuvor beschriebenen zellbasierten Assay zu finden 
und sollte so dessen Etablierung vereinfachen. Weiters erlaubt er uns, Proteasen 
unterschiedlicher Viren, unabhängig von deren Biosicherheitsstufe, in einem sicheren System 
zu untersuchen. 
 Eine inaktivierte Variante der modularen Protease wurde für Kristallisationsexperimente 
zur strukturellen Charakterisierung verwendet. Die Kristallisation war schwierig, vermutlich 
wegen der durch die Verbindung von Protease und Kofaktor induzierten Flexibilität. Daher war 
die Kristallisation erst dann erfolgreich und reproduzierbar, als die Protease mit dem Maltose 
bindenden Protein (MBP) als Fusionsprotein exprimiert wurde. Die resultierenden Kristalle 
waren zu klein und fragil um mittels Röntgenkristallographie analysiert zu werden, sind 
allerdings eine gute Basis für eine weitere Optimierung der Kristallisationsbedingungen und 
stellen einen wichtigen Schritt in Richtung der Aufklärung der Struktur der NS2B/3pro dar.  
 Die Ergebnisse der Dissertation erweitern das Verständnis der grundlegenden 
molekularen Mechanismen des FSME Virus und jenes über die Proteasen des FSME, HI und 
MKS Virus. Die beschriebenen Systeme ermöglichen es, unterschiedliche Aspekte der 
Pathogenese und der Entstehung von Inhibitorresistenzen zu untersuchen. Sie sind die Basis 
für eine Untersuchung der Beziehung zwischen Struktur und Funktion der Proteasen und 
sollten daher eine zukünftige Entwicklung von Proteaseinhibitoren vereinfachen.
  
5 General Introduction 
1. GENERAL INTRODUCTION 
1.1. Classification, taxonomy and clinical importance of flaviviruses 
1.1.1. Family Flaviviridae - Genus Flavivirus 
 The family of Flaviviridae contains three genera, the Flavivirus, Pestivirus and 
Hepacivirus. They are similar in terms of their replication strategy, morphology and composition 
of the viral genome. However, they lack serological cross-reactivity and differ in regard to their 
biological properties. The virions are small (50nm), spherical, enveloped particles with one or 
more membrane anchored glycoproteins. The envelope surrounds the nucleocapsid which is 
formed by multiple units of the capsid protein and the single-stranded positive-sense RNA 
genome. Upon infection, it is translated into a polyprotein which is subsequently processed into 
its individual proteins by virus and host cell proteases. Finally, the progeny viruses assemble by 
budding through the membranes of the endoplasmic reticulum (ER) (Lorenz et al., 2002). 
 
Figure 1. Classification of the genus Flavivirus. The serological (serocomplex) and phylogenetical 
(clade and cluster) classifications of these flaviviruses are shown on the right (adapted from 
Mukhopadhyay et al., Nature Reviews Microbiology, 2005). 
 
 The genus Flavivirus includes approximately 70 different viruses. Based on their route 
of transmission they can be divided into mosquito-borne, tick-borne and non-vectored viruses 
(Calisher et al, 1989). Furthermore, the viruses can be classified on the basis of serological 
criteria and sequence identity (Fig. 1) (Calisher et al., 1989; Kuno et al. 1998; Mukhopadhyay et 
al., 2005). The most important human pathogens are found among the mosquito-borne 
flaviviruses and include yellow fever virus (YFV), Japanese encephalitis virus (JEV), dengue 
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virus (DENV, subtypes 1, 2, 3 and 4) and West Nile virus (WNV) as well as one member of the 
tick-borne group, the tick-borne encephalitis virus (TBEV). Based on minor variations of their 
nucleotide sequence, TBEV is further classified into the European, the Far Eastern and Central 
Siberian subtype, each causing severe diseases with distinct clinical manifestations (Ecker et 
al., 1999). 
 
1.1.2. Tick-borne encephalitis virus 
 TBEV is endemic in an area ranging from Northern China and Japan through the former 
Soviet countries to Europe. However, there are no reported cases for the British Isles, the 
Benelux countries, Portugal and Spain (Mansfield et al., 2009). Humans are occasionally 
infected by the consumption of non-pasteurised milk products from viremic livestock or by 
inhaling aerosolised infectious virions. However, most of the infections are caused by the bite of 
a chronically infected tick (Süss, 2003), mostly of the species Ixodes ricinus (European 
subtype), Ixodes persulcatus (Eurasia) and Ixodes ovatus (North-eastern China and Northern 
Japan) (Gubler et al., 2007). A majority of TBE infections remains asymptomatic but the 
infection can also lead to severe neurological diseases. After an incubation time of 3 to 7 days, 
a flu-like sickness occurs. In 70 % of cases, the patients recover within a week. In 20 to 30 % of 
patients a second stage of illness may occur which correlates with severe diseases of the 
central nervous system (CNS), including symptoms of meningitis, meningoencephalitis or 
meningoencephalomyelitis. 10 to 20 % of these patients experience long-term neuropsychiatric 
complications, such as spiral nerve paralysis; 1 to 2 % die (Charrel et al., 2004). This mortality 
rate is only valid in European countries and is much higher in Siberia (6 -8 %) and Far East (20 
– 40 %). To prevent infection, a chemically inactivated whole virus vaccine derived from the 
prototypic European subtype, strain Neudoerfl, is available. The vaccine has proven to be 
efficient, safe and well-tolerated, and provides a 99 % protection rate after a basic 
immunisation of 3 doses. Booster doses are recommended every 3 to 5 years (Kunz et al., 
1991). In Austria, about 90 % of the population is vaccinated. However, there does not exist 
any specific antiviral therapy for TBE. Thus, once manifested, the disease is not curable (Kaiser 
et al., 2008). 
 
1.2. Molecular organisation of TBEV 
1.2.1. Virion structure 
 TBEV are relatively small (50 nm), spherical particles, which are surrounded by a host 
cell derived lipid envelope (Fig. 2) (Lindenbach, Thiel and Rice, 2007). In this envelope, two of 
the three structural proteins, the membrane protein (M) and the envelope protein (E), are 
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anchored via transmembrane helices (Zhang et al., 2003). The dense core of the particles 
contains the nucleocapsid (NC). It is composed of multiple copies of capsid protein (C) 
complexed with one copy of the viral RNA genome and does not seem to have a symmetrical 
structure. Glycoprotein E mediates attachment and entry of the virus and is the major target of 
the host´s immune response. Functional protein M is produced from precursor M (prM) protein 
during maturation of the viral particle. Hereby, a structural reorganisation of the prM-E 
heterotrimers into antiparallel homodimers is induced which flattens the surface of the mature 
virus particle (Fig. 2) (Stiasny and Heinz, 2006). 
 
Figure 2. TBEV particle. Schematic representation of the immature and mature flavivirus particle. NC, 
structural glycoproteins prM/M, E, and the lipid membrane are indicated. (adapted from Stiasny and 
Heinz, 2006). 
 
1.2.2. Genome organisation 
 The ~10.8-kb genome (Fig. 3) has only one open reading frame (ORF) and is infectious 
when introduced into a host cell. There, it is directly translated into a polyprotein that is 
subsequently cleaved into three structural proteins, C, prM and E and seven non-structural 
proteins, NS1 to NS5. 
 
 
 
Figure 3. TBEV genome organisation. Scheme of the single-stranded positive-sense RNA genome 
(not drawn to scale). The structural proteins are indicated in dark grey, the non-structural ones in light 
grey. See text for details. 
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The 5’ and 3’ non-coding regions (NCR) of the genome are rich in RNA secondary structure 
elements. They are involved in a variety of important processes such as RNA replication and 
packaging as well as translation and binding of host factors (Alvarez et al., 2005; Gritsun et al., 
1997; Khromykh et al., 2001; Kofler et al., 2006; Mandl et al., 1993). The 5´NCR is 
approximately 100 nucleotides long and carries a 5´type-I cap structure. The 3’ NCR is 775 to 
1125 nucleotides (nt) in length and can be further divided into a highly conserved core region 
(325 nt), involved in viral replication, and a variable region (450 to 800 nt) (Wallner et al., 1995; 
Markoff et al., 2003). In contrast to cellular messenger RNAs, it lacks a poly(A)tail (Lindenbach, 
Thiel and Rice, 2007). 
 
1.2.3. TBEV life cycle 
 Figure 4 shows a scheme of the TBEV life cycle. TBEV attaches to the host cell by 
interaction of the envelope protein E with one or more cellular receptors which have not been 
sufficiently identified yet. The ability to use multiple receptors might be responsible for the wide 
host range of flaviviruses, which replicate in arthropods and vertebrates. Several studies 
indicate an involvement of heparan sulphate (HS), a highly sulphated glycosaminoglycane that 
is found on many cell types, in TBEV attachment and entry (Kroschewski et al., 2003; Mandl et 
al., 2001; Germi et al., 2002). However, the availability of HS on the cell surface is not 
obligatory and its precise function remains unclear. After internalisation by receptor-mediated 
endocytosis, the virion is transported to prelysosomal endocytic vesicles (Chu et Ng, 2004), 
where the acidic environment induces a permanent trimerisation of the E protein. Thereby, the 
fusion peptide becomes exposed and inserts into the endosomal membrane; viral and cellular 
membranes (Allison et al., 1995; Heinz et al., 2003) fuse. As a result, the nucleocapsid is 
released into the host cell cytoplasm where capsid proteins and RNA dissociate. Translation is 
started immediately by the host cell translation machinery and results in one polyprotein that is 
cotranslationally integrated into the ER lumen (Mukhopadhyay et al., 2005). There, the 
polyprotein is processed by the host signal peptidase I (SPaseI) and the viral NS2B/3 protease 
(NS2B/3pro). This processing generates the mature, functional proteins; three of which are 
structural ones (C, prM and E) that compose the viral particle, seven are non-structural proteins 
(NS1, NS2A, NS2B; NS3, NS4A, NS4B and NS5) that play a role in all stages of viral RNA 
synthesis. After generation of the viral polymerase and other necessary non-structural proteins, 
a replicase complex is assembled. First, negative-strand RNA copies are generated, which in 
turn serve as templates for the production of plus strand genomic RNAs. These are capped by 
the viral NS3 and NS5 proteins, which act as both triphosphatase and RNA helicase, or 
methyltransferase and RNA polymerase, respectively. The glycoproteins E and prM are 
cotranslationally translocated into the ER lumen, where they are both glycosylated while they 
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are still unfolded. This indicates that glycosylation might support correct folding of prM and E 
proteins (Helenius et al. 2004). After SPaseI cleavage at their N-termini, both proteins remain 
attached to the ER membrane and associate into prM/E heterodimers. This association is the 
driving power for the budding of the nucleocapsid (NC). The NC is formed on the cytoplasmic 
site of the ER membrane, when protein C interacts with the viral genomic RNA. By budding into 
the ER, the viral envelope is acquired; as a by-product, capsidless, non-infectious subviral 
particles (SVP) are produced. These immature virions are then transported to the late trans-
Golgi Network (TGN), where prM is converted into its active form by the host protease furin 
(Stadler et al., 1997). This cleavage induces a structural reorganisation of protein E, resulting in 
the decomposition of the prM/E heterodimers. Instead, fusion-competent E protein homodimers 
are generated. Finally, Golgi vesicle and host cell plasma membrane fuse, thereby releasing 
mature virions and SVP (Mandl et al., 2005; Stiasny and Heinz, 2006). 
  
 
Figure 4. Flaviviral life cycle (adapted from Stiasny and Heinz, 2006). See text for details. 
 
1.2.4.  Capsid protein C and pre-matrix protein prM  
 The capsid protein C is located at the N-terminus of the precursor polyprotein. It is 
anchored in the ER membrane via a C-terminal hydrophobic region, which is highly conserved 
among flaviviruses and is responsible for the translocation of protein prM into the lumen of the 
ER (Nowak et al., 1989) (Fig. 5). Mature protein C (Amberg et al., 1994; Lobigs et al. 1993), 
with a high content of basic residues, a mass of 11 kDa and an isoelectric point of 13, is 
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released from the polypeptide chain by cleavage of the viral NS2B/3 protease. The 
nucleocapsid is formed by multiple copies of protein C that surround a single copy of the 
genomic RNA. The first three-dimensional model of the YFV and DENV-2 capsid protein was 
proposed by Jones et al., 2003, based on nuclear magnetic resonance (NMR) spectroscopy 
analysis. Ma et al, 2004 improved this structure by using the same method. Again in 2004, 
Dokland and colleagues succeeded in resolving the structure of the C protein of the Kunjin 
subtype of the WNV by using high-resolution X-ray crystallography. In good agreement with 
biochemical evidence (Jones et al., 2003; Kiermayr et al., 2004), the structural data suggest 
that the elementary unit of the NC is a dimer of protein C, with each subunit composed of four 
alpha helices (α1 to α4) that are interspersed by short loops (Fig. 5A and B).  
 
A 
 
B 
 
 
Figure 5. Capsid protein C. (A) Schematic diagram of TBEV protein C. The ER membrane is 
represented by a shaded field. The signal sequence for the translocation of prM into the ER as well as 
the cleavage sites of the viral NS2B/3 protease and the host signalase are indicated. (B) Views of the 
DV2 capsid protein dimer structure as determined by Ma et al., 2004. Alpha-helix α1 is shown in blue, α2 
in green, α3 in yellow and α4 in magenta (adapted from Mandl 2005). 
 
 Helices α2 and α4 are primarily responsible for the intra-dimeric interactions. The α4 
helices of both monomeric subunits interact with each other in a structural arrangement that 
has characteristics of a coiled-coil structure (Kofler et al., 2002; Ma et al., 2004). They form a 
surface containing a large number of positively charged side chains which presumably interacts 
with the negatively charged genomic RNA. This interaction is the basis for the formation of the 
NC. Hydrophobic helices α1 and α2 lie at the opposite site of the dimer and are responsible for 
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interactions with the membrane that surrounds the NC (Mandl et al. 2004) (Fig. 5B). Samsa et 
al., 2009 showed that protein C of DENV accumulates on the surface of ER-derived lipid 
droplets and that this amassment is important for the formation of viral particles. Substitution of 
only two amino acids in the hydrophobic core region of DENV protein C results in an 
accumulation of protein C in the cytoplasm rather than on lipid droplets. As a consequence, 
viral RNA synthesis is reduced. 
 
1.2.5.  Processing of flaviviral structural proteins 
 The TBEV polyprotein is integrated cotranslationally into the host cell´s ER membrane. 
This makes it impossible for the cytoplasmic viral protease to access the cleavage sites within 
the ER lumen. Therefore, viral and host cell proteases are required to process the polyprotein 
precursor into its mature proteins. Proteins prM and E are cotranslationally released from the 
polyprotein precursor by SPase I cleavage on the luminal side of the ER. In contrast, protein C 
and prM are separated by regulated cleavages by the viral NS2B/3pro and the host cell SPase I 
on both sides of the ER (Fig. 6). 
 
 
 
Figure 6. Topology of the flaviviral structural proteins across the ER membrane. Transmembrane 
helices are indicated by cylinders, cleavages sites for the various proteases are indicated by arrows 
(adapted from Mukhopadhyay et al., 2005). E, envelope; NS1, non-structural protein 1; prM, pre- 
membrane protein. 
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 The C-terminus of protein C of TBEV contains two putative NS2B/3pro cleavage motifs 
which are separated by one single amino acid. Furthermore, it bears an internal hydrophobic 
signal sequence which directs the translocation of the prM protein into the ER lumen. This 
signal sequence is removed by cleavage of the NS2B/3pro on the cytosolic side of the ER 
membrane, thereby liberating mature protein C (Amberg et al.; 1994, Yamshchikov et al., 
1994). Only after this cleavage has taken place, the signal peptide can move towards the ER 
lumen. As a consequence, the host cell SPaseI can assess its previously hidden cleavage site. 
Thereby, the N-terminus of protein prM is liberated, which in turn is important for the correct 
processing of protein E (Lorenz et al., 2002; Konishi et al., 1993). Mature protein C associates 
with the viral genome to form the nucleocapsid. By budding into the ER lumen, the viral 
envelope is acquired (Chambers et al., 1990). Budding is disturbed when the two cleavage 
events at the C-prM junction of the Murray Valley encephalitis virus polyprotein are uncoupled. 
As a result, the production of non-infectious SVP (Lobigs et al., 2004) is increased, 
emphasising the importance of this coordinated processing for efficient virion assembly 
(Amberg and Rice, 1999; Lobigs et al., 2004; Stocks et al., 1998). 
 
1.3. Viral proteases and their specificity 
1.3.1. TBEV NS2B/3 protease 
The viral protease NS2B/3 is formed by a complex made of the protease domain of the NS3 
protein and its cofactor, NS2B. The crystal structures of the protease domain of WNV and 
DENV-2 NS3 protein have already been determined. The same was accomplished for the full-
length NS3 protein of MVEV and DENV in complex with the central hydrophilic domain of the 
NS2B cofactor. (Fig. 7) (Aleshin et al., 2007; Assenberg et al., 2009; Erbel et al., 2006; Luo et 
al., 2008). However, until now a structure of the TBEV NS2B/3pro has not been determined. 
  The NS3 protein comprises a helicase as well as a triphosphatase activity in its C-
terminal domains. In addition, a protease activity is located at its N-terminus (Lobigs, 1992; 
Preugschat et al., 1990). The NS2B/3pro is a serine protease with a trypsin like fold, consisting 
of two ß-barrels with the catalytic triad (His51-Asp75-Ser135) being located in between. The 
hydrophilic core domain of the co-factor NS2B stabilises the protease and is also involved in 
substrate binding (Erbel et al., 2006). The N- and C-terminal flanking regions are rich in 
hydrophobic residues and anchor the NS3 protease complex to the ER membrane (Chambers 
et al., 1993; Clum et al., 1997). As a result, the protease is positioned near its cleavage sites, 
all of which are proximal to transmembrane regions (Bera et al., 2007). However, in vitro 
processing studies revealed that NS2B/3 precursors are capable of performing self-cleavage 
also in the absence of membranes (Shiryeav et al., 2007; Erbel et al., 2006; Chambers et al., 
1995; Pugachev et al., 1993).  
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 Without the NS2B domain, the NS3 protease is proteolytically inert. However, it has 
been shown by Leung et al. (2001) that the full length NS2B sequence can be substituted with 
its 35-48-residue core region without any loss of cofactor activity. Based on this knowledge, 
several groups have generated proteolytically active single chain NS2B-NS3 modular 
proteases by coupling the NS2B core region to the NS3 protease domain by a synthetic nona-
peptide linker. Although this linker replaces the NS2B/3pro cleavage site at the NS2B/NS3 
junction, some of these proteases still exhibited auto-catalytic activity (Chappell et al., 2007, 
Shiryaev et al., 2007). 
 The TBEV NS3 protease usually cleaves after two basic amino acid residues at the P2 
and P1 positions (nomenclature according to Schechter et al., 1967) followed by one with a 
short, uncharged side chain (Chambers et al., 1990; Rice et al., 1990). At the C-prM junction, 
the TBEV exhibits two potential NS2B/3 cleavage motifs which are separated by a single amino 
acid. Schrauf and co-workers (2009) showed that, in vivo, the downstream cleavage site is 
predominantly used and that the upstream cleavage motif cannot be accepted when the 
downstream cleavage motif had been removed by mutation. 
 
Figure 7. Structure of the NS2B-NS3 complex in the absence (A) or presence (B) of an inhibitor. 
(A) Open DEN NS2B-NS3 complex. (B) WNV NS2B-NS3 complex with bound inhibitor. NS2B is shown 
in yellow, NS3 in grey, the inhibitor in orange. Adapted from Erbel et al., 2006. 
 
1.3.2. Foot and Mouth Disease Virus (FMDV) 3C protease 
 FMDV is a member of the Aphtovirus genus in the Picornaviridae family, an important 
group of mammalian single-strand, positive-sense RNA viruses that includes human rhinovirus, 
poliovirus and hepatitis A virus (Mason et al., 2003). The viral genome is translated as a single 
polyprotein that is cleaved into functional proteins by a virally encoded leader (Lpro) and 3C 
protease (3Cpro) (Fig. 8).  
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Figure 8. Processing of the FMDV polyprotein. 3C protease cleavages are indicated by arrows. 
Adapted from Curry et al., 2006. 
 
 During translation, the Lpro is liberated from the N-terminus of the polyprotein by autolytic 
processing. A ribosomal skip mechanism inhibits correct peptide bonding at the C-terminus of 
protein 2A and is therefore responsible for the separation of structural and non-structural 
proteins (Mason et al., 2003). Ten of the 13 cleavages are performed by the highly conserved 
3Cpro (Curry et al., 2006). Furthermore, the 3Cpro is responsible for several cleavages of 
transcription and translation-associated host cell proteins. In this way, the protease contributes 
to a pronounced inhibition of host-cell protein synthesis (Belsham et al., 2000; Li et al., 2001) 
while at the same time promoting viral replication.  
 Recent structural work on FMDV 3Cpro (Birtley et al, 2005; Sweeney et al, 2006; Yin et 
al, 2005) shows that its catalytic domain adopts a conformation similar to chymotrypsin-like 
serine proteases (Hedstrom et al., 2002). Nevertheless, in accordance with its catalytic triad 
being Cys163-His46-Asp84 (Birtley et al., 2005), the FMDV 3Cpro is a member of the rare group 
of chymotrypsin-like cysteine proteases (Barret & Rawlings, 2001). Presumably, Asp84 forms 
hydrogen bonds with His46 of the catalytic triad and is stabilised by Ser182. Even though these 
interactions have parallels with those of other, well studied, chymotrypsin-like serine proteases, 
the exact catalytic mechanism of FMDV 3Cpro remains unclear. 
 
Figure 9. Sequence logos of the polyprotein junctions cleaved by FMDV 3C
pro
. Adapted from Curry 
et al., 2006. 
 Like other picornaviral 3C proteases, the FMDV 3Cpro processes peptide sequences 
with a hydrophobic residue at P4, such as proline or isoleucine, a glutamine residue at P1 and 
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a small hydrophobic amino acid at P1´. However, unlike other picornaviral proteases, the 
FMDV 3Cpro tolerates larger residues at P1´ and cleaves sequence motifs with P1-glutamate at 
rates similar to those with P1-glutamine (Fig. 9) (Curry et al., 2006). The significance of P4, P1 
and P1´positions was confirmed by Birtley et al., 2005. 
 
1.3.3. Human Immunodeficiency Virus (HIV-1) protease 
 HIV is a member of the Retroviridae family, genus lentivirus (van Regenmortel et al., 
2009). On the basis of serological properties and sequence analysis of the genome, the HIV 
isolates are grouped into two types, HIV-1 and HIV-2. HIV-1 is the most common and 
pathogenic one. 
 The positive sense single stranded RNA genome of HIV is 9.2 kb long. It is flanked by 
long terminal repeats (LTR) that regulate viral integration into the host genome, as well as 
several phases of viral gene expression. From the unspliced polycistronic mRNA, two large 
large precursor polyproteins, Gag and Gag-Pol, are translated. These are subsequently 
processed by the virally encoded, autocatalytically excised protease (HIVpro) to yield the mature 
viral proteins (Frankel et al., 1998; Vogt et al., 1996). The protease, together with the viral 
reverse trancriptase and integrase, are products of the pol open reading frame. The structural 
proteins (matrix, capsid and nucleocapsid, and the peptides p1, p2 and p6) are generated by 
processing of the gag polyprotein.  
 
Table 1. Processing sites in gag and gag-pol polyproteins recognized by HIV-1 protease. Adapted 
from Ozer et al., 2006. 
Substrate sites in the Gag Polyprotein  
matrix–capsid (ma–ca) SQNY*PIVQ 
capsid–p2 (ca–p2) ARVL*AEAM  
p2–nucleocapsid (p2–nc) ATIM*MQRG 
p1–p6 PGNF*LQSR  
nucleocapsid–p1 (nc–p1) RQAN*FLGK 
Substrate sites in the Pol polyprotein  
reverse transcriptase–RnaseH (rt–rh) AETF*YVDG  
RnaseH–integrase (rh–in) RKIL*FLDG  
protease–reverse transcriptase (pr–rt) TLNF*PISP  
transframe–protease (tf–pr) SFNF*PQIT 
  
 The HIV-1 protease is an aspartic protease that is active as a homodimer. The two 
identical subunits are non-covalently associated (Lapatto et al., 1989; Navia et al., 1989; 
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Wlodawer et al., 1989). Each monomer is encoded by 99 amino acids and consists of nine β-
sheets and one α-helix. The catalytic triad (Asp25, Thr26 and Gly27) lies in a loop at the end of 
the third ß-sheet; the active site is formed at the dimer interface, where each subunit 
contributes one catalytically relevant aspartic acid residue (Asp25). The N-termini of each 
subunit contribute to dimer stability (Ishima et al., 2000; Louis et al., 2003) whereas the C-
termini are essential for dimerisation.  
 The HIV-1 polyprotein is processed by the HIV-1 protease at unique sites. Although a 
comparison of these sequences reveal a broad substrate specificity and the absence of a 
consensus sequence, these sites share several characteristics (Debouck et al., 1992). All HIV 
proteases prefer hydrophobic residues at the P1 and P1’, small ones at the P2, aliphatic and 
glutamine/glutamiate residues at the P2’ position; aromatic side chains are poorly accepted at 
P3’ position. In contrast to cellular aspartic proteases, HIV-1 proteases recognise sequences 
which bear an aromatic residue such as tyrosine or phenylalanine at P1, followed by proline at 
P1´ (Pettit et al., 1991; Roberts et al., 1990). This property, together with its significance in the 
viral life cycle, makes the protease an important target for antiviral therapy (Sommadossi et al., 
1999; Wlodawer et al., 1993). Although several inhibitory compounds have already been 
developed, their clinical utility is limited by the emergence of drug resistant viruses. 
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2. AIMS 
 Proteolysis by virally encoded enzymes is essential for the replication of many viruses 
(Krausslich and Wimmer 1988; Hellen et al., 1989). This makes protease inhibitors an 
important target for the antiviral therapy. However, the development of such inhibitors is 
difficult, as viral proteolysis is a highly complex process. Cleavage sites are often insufficiently 
defined and the development of resistance to inhibitors due to the high mutation rate of the viral 
RNA polymerase is an enduring problem.  
 To overcome these difficulties, detailed information on substrate specificity of the 
proteases and their resistance to inhibitors is needed. Therefore, novel systems are required 
that allow the generation of a large number of escape mutants in a random manner and to 
analyse them systematically. Thus, the overall objective of this work is to develop a sensitive 
system that allows us to examine the properties of various viral proteases. As an RNA virus, 
the TBEV itself could be used as such a tool. It produces a large number of mutants due to its 
error-prone polymerase, with approximately one error per synthesised genome. Thus, the 
presence of suboptimal substrates or protease inhibitors should provoke the production of 
infectious escape mutants. These can be easily selected over non-infectious virions by 
measuring their infectivity. Finally, analysis of the escape mutants should give important 
insights into the mechanisms leading to resistance to protease inhibitors.  
 
Aim 1: Establishment of a cell based system to investigate various viral proteases 
 To establish a system that allows us to investigate several distinct proteases, we 
intended to modify the genome of TBEV in such a way that the production of infectious virions 
becomes dependent on the activity of a heterologous protease instead of the TBEV protease 
(NS2B/3pro). To this end, the NS2B/3pro capsid cleavage site in the C-terminal region of TBEV 
should be replaced by a heterologous cleavage site such as that of the FMDV 3Cpro or HIV-1pro. 
The infectivity of these non-infectious mutants should then be regained by providing the 
corresponding heterologous protease either in cis or in trans. The establishment of such a 
system should allow us to study the substrate specificity of these heterologous proteases and 
to investigate its ability to become resistant to a corresponding inhibitor (manuscript 1). 
 
Aim 2: Establishment of a biochemical system to investigate the NS2B/3pro and  
to find suitable substrates needed to accomplish aim 1 
 To generate the above mentioned mutants of TBEV, with cleavage sites for a 
heterologous protease instead of one for the NS2B/3pro, it is important to have a profound 
understanding of the cleavage mechanism and substrate specificity of the NS2B/3pro. To this 
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end, we intend to establish a biochemical assay that allows us to investigate in vitro the 
cleavage of the NS2B/3pro. Once established, this assay should be modified in a way to allow 
investigation of other viral proteases. This assay should then be used to test the suitability of 
diverse substrates to be processed by various heterologous proteases (e.g. HIV-1 protease) as 
described in aim 1 (manuscript 2). 
 
Aim 3: Determination of the three dimensional structure of the TBEV NS2B/3pro 
 Finally, we intended to determine the structure of the TBEV NS2B/3pro by X-ray 
crystallography. To this end, expression and purification protocols should be optimised to yield 
NS2B/3 protein in a quantity and quality sufficient for structure determination. A 3D structure of 
the physiologically relevant NS2B/3pro would represent a significant impulse for the 
development of antiviral substances against TBEV (manuscript 3). 
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Mature protein C of tick-borne encephalitis virus (TBEV) is cleaved from the polyprotein precursor
by the viral NS2B/3 protease (NS2B/3pro). We showed previously that replacement of the NS2B/
3pro cleavage site at the C terminus of protein C by the foot-and-mouth disease virus (FMDV) 2A
StopGo sequence leads to the production of infectious virions. Here, we show that infectious
virions can also be produced from a TBEV mutant bearing an inactivated 2A sequence through
the expression of the FMDV 3C protease (3Cpro) either in cis or in trans (from a TBEV replicon).
Cleavage at the C terminus of protein C depended on the catalytic activity of 3Cpro as well
as on the presence of an optimized 3Cpro cleavage site. Passage of the TBEV mutants bearing a
3Cpro cleavage site either in the absence of 3Cpro or in the presence of a catalytically inactive
3Cpro led to the appearance of revertants in which protein C cleavage by NS2B/3pro had been
regained. In three different revertants, a cleavage site for NS2B/3pro, namely RR*C, was now
present, leading to an elongated protein C. Furthermore, two revertants acquired additional
mutations in the C terminus of protein C, eliminating two basic residues. Although these latter
mutants showed wild-type levels of early RNA synthesis, their foci were smaller and an
accumulation of protein C in the cytoplasm was observed. These findings suggest a role of
the positive charge of the C terminus of protein C for budding of the nucleocapsid and further
support the notion that TBEV protein C is a multifunctional protein.
INTRODUCTION
Tick-borne encephalitis virus (TBEV), from the family
Flaviviridae, is an enveloped, positive-stranded RNA virus.
Its genome is translated into one large polyprotein that
traverses the endoplasmic reticulum (ER) several times.
This polyprotein is co- and post-translationally cleaved by
viral and cellular proteases (Lindenbach et al., 2007). For
productive infection, proteolytic processing and assembly
of the virus particle must be closely co-ordinated (Amberg
& Rice, 1999; Lindenbach et al., 2007). Structural protein
processing leads ultimately to the formation of protein
C and the two glycoproteins prM (membrane) and E
(envelope) (Lobigs, 1993). The latter remain anchored in
the ER membrane, whereas mature protein C participates
in RNA packaging and particle assembly with the newly
synthesized mRNA to form the nucleocapsid (Mandl,
2005). Preformed nucleocapsid has not yet been detected in
infected cells. Given that budding of flavivirus membranes
is driven by the interactions of prM and E independently of
protein C or the assembled nucleocapsid (Lobigs & Lee,
2004), the co-ordinated cleavage events at the C–prM
junction appear to be a key to the efficient incorporation of
nucleocapsid during flavivirus assembly.
Cleavage by the viral protease NS2B3 (NS2B/3pro) in the
C-terminal region of protein C is a prerequisite for the
subsequent signallase cleavage inside the lumen of the ER
that generates the N terminus of prM (Amberg & Rice,
1999). The signallase cleavage site of prM is thought to be
maintained in a predominantly cryptic conformation until
cleavage of C by NS2B/3pro. This prevents cotranslational
signallase cleavage of prM and should result in transient
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expression of a C–prM intermediate at the putative
flavivirus assembly site on the ER membrane until cytosolic
processing by the viral protease has taken place (Lobigs &
Lee, 2004). The importance of the concerted progression
of the cleavage events at the C–prM junction has been
documented in yellow fever virus, Murray Valley enceph-
alitis virus and TBEV. Inhibition of protein C cleavage or
disturbance of the cleavage order interfered with or even
abrogated viral growth and infectivity (Amberg & Rice,
1999; Chappell et al., 2005; Lee et al., 2000; Lobigs & Lee,
2004; Schrauf et al., 2008; Stocks & Lobigs, 1998).
The exact position of the TBEV NS2B/3pro protein C
cleavage site and the cleavage sequence itself are highly
flexible (Schrauf et al., 2008). Furthermore, this NS2B/3pro
cleavage site can be replaced by the FMDV (foot-and-
mouth disease virus) 2A protein sequence in both TBEV
and West Nile Virus (WNV) (Schrauf et al., 2009). This 2A
sequence enables the release of mature protein C from
the polyprotein in the absence of proteolysis through a
‘StopGo’ mechanism that promotes reinitiation on the
translating ribosome (Atkins et al., 2007). The release of
protein C thus occurs co-translationally and prematurely
compared with that in the wild-type. In addition, the
mechanism of action of FMDV 2A results in a protein C
with a 19 aa C-terminal extension. Examination of the
resulting TBEV mutants showed an altered buoyant density
and a reduction of early RNA synthesis upon viral infection
but not with electroporation of naked RNA, suggesting
previously unrecognized roles of protein C in uncoating
and/or early RNA replication (Schrauf et al., 2009).
Here, we further characterize the function(s) of protein C by
making the C/prM cleavage dependent on the synthesis of a
heterologous protease, the FMDV 3Cpro (Curry et al., 2007).
RESULTS
Constructing a system allowing protein C
cleavage to be performed by a heterologous
protease
TBEV variants in which the NS2B/3pro cleavage site at the C
terminus of the protein C had been replaced by the 20 aa
FMDV 2A protein still produce infectious virions (Schrauf
et al., 2009). Generation of the mature protein C is accom-
plished by a ‘StopGo’ mechanism in which a PGP motif
located at the C-terminal end of the FMDV 2A protein
causes the ribosomes to skip peptide bond formation
(Donnelly et al., 2001).
Mutants lacking the PGP motif cannot perform the StopGo
process, preventing separation of protein C from prM and
consequently virion production, even in the presence of
viral RNA and protein synthesis. Could the expression of
the 3Cpro of FMDV rescue mutants lacking PGP by cleaving
between the C terminus of protein C and the N terminus the
FMDV 2A sequence? To address this question, we took the
mutant TBEV 2AD3 (Fig. 1a) (Schrauf et al., 2009) lacking
the PGP motif at the C terminus of 2A. At the N terminus of
the 2A sequence, there is a suboptimal cleavage motif for
the FMDV 3Cpro, RGKQ*TLN (the asterisk indicates the
cleavage site). To improve this cleavage site, we inserted the
amino acids PV and QV between the glycine and lysine
residues, optimizing the P4 and P3 positions (Fig. 1a). It has
been previously demonstrated (Birtley et al., 2005) that the
P4 position is also important for 3Cpro cleavage. To further
enhance the system, we also introduced the mutation E122G
into protein E (PV-2AD3-H and QV-2AD3-H, Fig. 1a). This
substitution enables the virus to use heparan sulphate to
bind to BHK-21 cells, thus increasing the specific infectivity
and binding affinity by up to 10-fold (Kroschewski et al.,
2003).
To express FMDV 3Cpro, we used a TBEV replicon lacking
the coding region for the structural proteins prM and E
(Fig. 1b). This replicon cannot produce infectious viral
particles on its own but can replicate RNA and express a
heterologous protein from a second ORF at the 39 end
(Gehrke et al., 2005). We placed the FMDV 3Cpro coding
sequence after the EMCV IRES element (DME-I-3C, Fig.
1b). We also prepared a replicon expressing an inactive
3Cpro (DME-I-3Ci, Fig. 1b).
The rationale was that when one of the TBEV 2AD3 mutants
and the protease-encoding TBEV replicon are present within
the same cell, the FMDV 3Cpro expressed from the replicon
should recognize its cleavage motif at the C–prM junction of
the TBEV-2AD3 mutant. This will liberate mature protein C
from the signal sequence for prM and allow the signallase
to access its cleavage site at the N terminus of prM. These
cleavages then enable the generation of all structural pro-
teins leading to the production of single-round infectious
particles.
Heterologous expression of the FMDV 3C
protease results in virion production
To ensure that replication and protein production still
function correctly, we first singly transfected BHK-21 cells
with RNAs of DME-I-3C, PV-2AD3-H and QV-2AD3-H.
Viral protein expression was analysed after transfection
and after the first passage of the supernatant by immuno-
fluorescence (IF) using an antiserum that predominantly
recognizes the structural protein E as well as the non-
structural protein NS1. Cells transfected with all RNAs
showed viral protein expression (Fig. 2a, upper panel).
Thus, all RNAs were competent for RNA replication, as we
have previously shown that only replication-competent
mutants generate and process sufficient proteins to be
visible by IF (Kofler et al., 2002). The efficiencies of
transfection were approximately 30–40% for DME-I-3C
and 80% for PV-2AD3-H and QV-2AD3H (Fig. 2a, upper
panel). As the replicons do not express protein E, it is
possible that the efficiency of their transfection is under-
estimated compared with those of the modified viruses
that express both protein E and NS1 that can be recog-
nized by the antiserum used. Twenty-four hours later,
TBEV mutants dependent on FMDV 3C protease
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phase-contrast microscopy revealed that cells transfected
with these showed a strong cytopathic effect (CPE) with
the concomitant death of the majority of cells. Passaging of
supernatants from the transfected cells did not, however,
lead to the production of viable virus (Fig. 2a, lower
panel).
We then transfected PV-2AD3-H or QV-2AD3-H RNAs
together with RNA from the replicon DME-I-3C. After
24 h, cells stained almost 100% positive for viral protein
expression (Fig. 2b, upper panel), indicating a high
electroporation efficiency. As the two replicating con-
structs both produce the NS1 protein, the antiserum
(predominantly recognizing proteins E and NS1) cannot
distinguish between them; therefore, we were not able
to determine how many cells were double-positive.
Nevertheless, IF analysis of singly transfected cells (80–
90% for the TBEV-mutant RNAs and 30–40% for the
DME-I-3C replicon RNA) indicated that at least 20–30%
of the co-transfected cells expressed both constructs. We
then used the supernatants of the electroporated cells to
infect fresh BHK cells. Using supernatants transfected with
the RNAs PV-2AD3-H and DME-I-3C, about 40–50% of
the fresh BHK cells were positive for the production of
viral proteins as detected by IF using the antiserum
staining for the proteins E and NS1, indicating that
virions had been produced by doubly transfected cells
(Fig. 2b, lower panel). In contrast, no positive cells were
observed with supernatants from cells transfected with
QV-2AD3-H or DME-I-3C RNA (Fig. 2b), suggesting that
Fig. 1. Structural organization of flavivirus mutants. (a) Drawing of the TBEV full-length genome and expanded views of the
protein C of TBEV WT and each TBEV mutant (not drawn to scale). The NS2B/3 cleavage site is underlined and the cleavage
position is marked by an asterisk. The inserted FMDV 2AD3 protein sequence is surrounded by a dashed line. The amino acids
PV and QV preceding residue K96 were inserted to optimize the FMDV 3Cpro cleavage sequence. The numbers at the top refer
to the amino acid positions within protein C. (b) Diagram of the TBEV genome and an expanded view of the structural protein
region and the 39NCR of each constructed TBEV replicon. The 3Cpro sequence was amplified by PCR from the FMDV strain O/
SAR/19/00 and placed behind an EMCV IRES as described in methods. Engineered mutations are shown with the
corresponding designation.
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the only cleavage site recognized was that with the optimal
PV sequence at P3 and P4.
Virion production depends on expression of an
active 3C protease
The above results implied that the FMDV 3Cpro could
rescue the defect in PV-2AD3-H. To provide further
evidence and to exclude any involvement of NS2B/3pro, we
constructed a DME replicon containing an inactive 3Cpro
(DME-I-3Ci; Fig. 1b) in which the active site cysteine
(Cys163) had been mutated to alanine. Cells transfected
with DME-I-3Ci RNA alone showed viral protein expres-
sion and a CPE (Fig. 2a and data not shown). However,
the supernatant of cells co-transfected with DME-I-3Ci
and PV-2AD3-H RNAs did not contain any infectious
particles (Fig. 2b). This strengthens the notion that an
active 3Cpro is required for virion production from PV-
2AD3-H and that the 3Cpro can replace the NS2B/3pro in
protein C cleavage.
Fig. 2. Cotransfection of TBEV PV-2AD3-H and QV-2AD3H with TBEV replicons expressing active or inactive 3Cpro. (a and b)
BHK-21 cells were transfected with mutant RNAs or were mock transfected and viral protein expression was detected with a
polyclonal serum 1 day post-transfection. Supernatants harvested 1 day post-electroporation were used to inoculate fresh
BHK-21 cells (arrows), and viral protein expression monitored by IF 1 day post-infection (bottom of panels a and b).
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Protein prM is only formed in the presence of an
active 3C protease
To assess protein processing at the C–prM junction in
cells transfected with full-length TBEV mutants and the
DME replicons, we examined protein prM production. All
constructs used [i.e. the full-length TBEV mutants (Fig.
1a) and the DME replicon (Fig. 1b)] code for protein C;
therefore, its analysis provides no information on 3Cpro
cleavage. However, protein prM is only expressed in cells
containing the TBEV mutants when 3Cpro cleaves at the
cytoplasmic side of the signal sequence for prM, allowing
the signallase access to its cleavage site at the N terminus of
protein prM. We therefore lysed cells transfected with
various RNAs 22 h after transfection and detected the
structural proteins E and prM with polyclonal antisera
raised against all structural proteins of TBEV and against
prM itself, respectively (Fig. 3). A prominent band
corresponding to protein E, indicating viral protein
synthesis and processing, was detected in lysates of cells
transfected with a full-length TBEV mutant (Fig. 3, upper
panel). In contrast, the band was absent from the lysate
transfected with the DME replicon alone. With the anti-prM
serum (Fig. 3, lower panel), a prominent band with a size
corresponding to that of protein prM was only detected in
lysates of cells transfected with combinations of PV-2AD3-
H+DME-I-3C or PV-2AD3+DME-I-3C (Fig. 3, lower
panel, lanes 4 and 7). Cell lysates of the full-length TBEV
mutants with the PV-2AD3 motif either alone or in
combination with DME-I-3Ci failed to produce any protein
prM, indicating no protein processing at the C–prM
junction in the absence of an active 3Cpro. Furthermore,
no protein prM was visible in lysates from cells transfected
with RNAs containing the QV-D3-H motif alone or in
combination with the 3Cpro, indicating that the 3Cpro
cleavage requires a suitable P4 residue. We did not, however,
observe any uncleaved C-2AD3-prM protein in the Western
blot with the anti-prM antiserum (Fig. 3, lower panel). We
believe that this is due to the high background at the
predicted position (about 35 kDa) as well as a previously
observed inability of this antiserum to recognize the C–prM
protein. No differences were visible between lysates contain-
ing the PV-2AD3 mutant with or without the heparan
sulphate mutation; hence, this additional mutation has no
impact on processing of the structural proteins (Fig. 3, lanes
4 and 7).
Supplying the 3C protease in cis also results in
TBEV mutant virion production
Can 3Cpro also be provided in cis? Accordingly, we con-
structed full-length TBEV mutants containing the 3Cpro
cleavage motif P-V-K-Q*T at the C terminus of protein C as
well as the coding region for an active or inactive 3Cpro as a
second cistron under IRES control (Fig. 4a). The protein E
heparan sulphate mutation was present in all constructs.
RNAs of PV-2AD3-H-I-3C and PV-2AD3-H-I-3Ci were
transfected into BHK-21 cells and viral protein expression
was examined by IF analysis (Fig. 4b, upper panel). About
30–40% of cells transfected with both mutants exhibited a
positive IF staining, indicating that both mutants were
competent for replication and protein expression. Next,
supernatants of the transfected cells were applied to fresh
cells and infection of these cells was again monitored by IF
(Fig. 4b, lower panel). RNA from PV-2AD3-H-I-3C pro-
duced infectious virions and could be propagated further
as indicated by the detection of positive cells after the first
passage. No infectious virions were obtained with PV-
2AD3-H-I-3Ci containing an inactive 3Cpro.
Thus, the presence of the 3Cpro cleavage site and the 3Cpro
sequence on the same genome also allows virion produc-
tion. However, the efficiency was lower than when 3Cpro
was supplied in trans.
Passage of 3C protein C cleavage site mutants in
the absence of an active 3C protease provokes
resuscitating mutations
Now, we wished to examine how quickly mutants could
arise in the absence of an active 3Cpro that would allow the
formation of a new NS2B/3pro protein C cleavage site and
thus lead to the production of infectious virions. Accordingly,
passaging experiments on BHK-21 cells were performed.
First, in vitro-synthesized RNAs of PV-2AD3-H, QV-2AD3-
H, PV-2AD3-H-I-3Ci as well as PV-2AD3-H together with
RNA of the replicon DME-I-3Ci were electroporated into
BHK-21 cells. Then, supernatants from the transfected cells
Fig. 3. Western blot analysis of structural
protein processing. Cells transfected with
mutant RNAs were lysed 22 h post-transfec-
tion, and structural proteins prM and E were
detected using polyclonal sera. Positions of
marker proteins in kDa are marked
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were harvested 1 or 2 days post-transfection and transferred
onto fresh BHK-21 cells; infection of cells was determined by
IF. Cells inoculated with supernatants from day 1 were all
negative for viral protein expression (Fig. 5a). Surprisingly,
however, in one of three attempts, 100% of the cells
inoculated with 2 day supernatants derived from PV-2AD3-
H transfected cells and about 50% of cells inoculated with
those from QV-2A3D-H and PV-2AD3-H-I-3Ci exhibited
a bright IF staining (Fig. 5a), indicating the production of
infectious virions. In contrast, no positive IF was observed
with supernatants from cells transfected with the two RNAs
PV-2AD3-H+DME-I-3Ci (data not shown).
To identify the responsible mutations, viral RNA was
isolated from supernatants 3 days post-infection of the
second passage and the entire structural protein-coding
region (C–prM–E), as well as the domain comprising the
heterologous inactive 3C protease was sequenced. No
mutations were found within the protease domain;
however, all three mutants had acquired a one nucleotide
insertion and a one nucleotide deletion in the structural
protein coding region that led to a short change of the
reading frame. In PV-2AD3-H, 6 aa within the 2AD3
protein sequence were provided from another reading
frame (Fig. 5b). In contrast, QV-2AD3-H and PV-2AD3-H-
I-3Ci, 22 aa in the C-terminal region of protein C and the
2AD3 protein sequence were provided from the same
reading frame as in PV-2AD3-H (Fig. 5b). These alterations
not only changed 2AD3 hydrophobicity but also intro-
duced a potential NS2B/3pro cleavage motif of R-R*C at
identical locations in all three revertants.
To ensure that these frame-shifts were responsible for the
restoration of infectivity, we introduced the mutations
observed in Fig. 5 into the full-length TBEV-2AD3 clone and
transfected the RNAs PV-2AD3-mut1, PV-2AD3-mut2 and
QV-2AD3-mut into BHK-21 cells. Infectious virions were
indeed obtained after passage of the transfection super-
natants (data not shown). These passaging experiments also
revealed that the virions of PV-2AD3-mut2 and QV-2AD3-
mut had a lower infectivity than PV-2AD3-mut1, possibly
due to the changes in protein C.
Was the sequence R-R*C being recognized by the TBEV
NS2B/3pro? Accordingly, we transfected BHK-21 cells
with WT-TBEV and mutant RNAs and lysed cells 48 h
Fig. 4. Analysis of TBEV mutants expressing the 3Cpro cleavage site and the 3Cpro on the same construct. (a) Schematic of
TBEV full-length mutants with the PV-2AD3 insertion within the C-terminal region of protein C, the heparan sulphate mutation in
E and the 3Cpro. (b) IF analysis of viral protein expression and viral infectivity. BHK-21 cells were transfected with mutant RNAs
or were mock transfected, and viral protein expression was detected by IF with the polyclonal serum 1 day post-transfection
(top). Supernatants harvested 1 day post-electroporation were also transferred onto fresh BHK-21 cells (arrows), and viral
protein expression monitored by IF 1 day post-infection (bottom).
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post-transfection. As expected, WT-TBEV lysates showed
prominent bands for the structural proteins E, prM and C
(Fig. 6, lane 2), whereas the mutants showed only prM and E
but no C band. Instead a new band was visible, termed C*
(Fig. 6, lane 3, 4 and 5), running slightly slower than the wild-
type. The size would correspond to a protein C extended by
14 aa, further indicating that the R-R*C motif is processed by
the NS2B/3pro. Moreover, the ratio of intracellular protein C
to the surface proteins prM and E differed in the mutants.
Thus, PV-2AD3-mut1 has a C/E ratio similar to that of the
WT-TBEV, whereas PV-2AD3-mut2 and QV-2AD3-mut
(Fig. 6, lane 4 and 5) show a much higher ratio, suggesting
that protein C accumulates in the cytoplasm.
QV-2AD3-mut1 and PV-2AD3-mut are impaired in
viral spread
To determine differences in infectious virus progeny
production, we examined the ability of the revertants to
form foci. WT-TBEV was used as a positive control. As a
further control, TBEV-2A was included into the experi-
ments, as its protein C comprises four amino acids more
than the second-site revertants and has already been
characterized. TBEV-2A foci are 10 times smaller than
those produced by the WT-TBEV, and can only be
visualized 70 h post-infection, clearly indicating a defect
in viral spread (Schrauf et al., 2009). Interestingly, despite
the 14 aa extension of its protein C, foci formed by PV-
2AD3-mut1 were only marginally smaller than those
formed by the WT-TBEV and could be detected 50 h
post-infection (Fig. 7a, bottom). In contrast, PV-2AD3-
mut2 and QV-2A3D-mut formed foci that could be
visualized only 70 h post-infection and were considerably
smaller than those of the WT-TBEV. However, they were
still about three to four times larger than those of TBEV-2A
(Fig. 7a, top).
To quantify the observed differences in infectivity, we
compared the growth properties of WT-TBEV, TBEV-2A
and the three second site mutants. We performed multistep
growth curves in BHK-21 cells at a low m.o.i. of 0.01 as
shown in Fig. 7(b). As previously observed (Schrauf et al.,
2009), TBEV-2A showed a delayed and reduced particle
release. In contrast, PV-2AD3-mut1, which forms large
foci, produced infectious progeny close to WT level,
whereas QV-2AD3-mut1 and PV-2AD3-mut2 showed
infectivity titres 1 and 1.5 log units below those of the
WT but still between 2.5 and 1.5 log units higher than
TBEV-2A (Fig. 7b).
PV-2AD3-mut1 exhibits a delay in the onset of
early RNA replication
The observed defects in infectivity and viral spread of
TBEV-2A were proposed to result from an impairment of
unpackaging and early RNA synthesis (Schrauf et al.,
2009). To determine the effect of protein C extensions of
the revertants on viral replication, we examined early RNA
F
ig
.
5
.
E
m
er
g
en
ce
o
f
P
V
-2
A
D
3
-H
,
Q
V
-2
A
D
3
-H
an
d
P
V
-2
A
D
3
-H
-I
-3
C
i
se
co
nd
-s
ite
re
ve
rt
an
ts
w
hi
ls
t
p
as
sa
g
in
g
w
ith
o
ut
th
e
co
rr
es
p
o
nd
in
g
3
C
p
ro
o
r
an
in
ac
tiv
e
3
C
p
ro
,
re
sp
ec
tiv
el
y.
(a
)
IF
an
al
ys
is
o
f
p
ro
te
in
ex
p
re
ss
io
n
an
d
vi
ra
li
nf
ec
tiv
ity
.B
H
K
-2
1
ce
lls
w
er
e
tr
an
sf
ec
te
d
w
ith
P
V
-2
A
D
3
-H
,Q
V
-2
A
D
3
-H
an
d
P
V
-2
A
D
3
-H
-I
-3
C
iR
N
A
an
d
th
e
vi
ra
l
p
ro
te
in
ex
p
re
ss
io
n
w
as
d
et
er
m
in
ed
1
d
ay
p
o
st
-e
le
ct
ro
p
o
ra
tio
n.
S
up
er
na
ta
nt
s
ha
rv
es
te
d
1
d
ay
p
o
st
-t
ra
ns
fe
ct
io
n
w
er
e
tr
an
sf
er
re
d
o
nt
o
fr
es
h
B
H
K
-2
1
ce
lls
(a
rr
o
w
s)
,
an
d
th
e
vi
ra
lp
ro
te
in
ex
p
re
ss
io
n
w
as
d
et
ec
te
d
b
y
IF
st
ai
ni
ng
1
d
ay
p
o
st
-i
nf
ec
tio
n.
S
up
er
na
ta
nt
s
ha
rv
es
te
d
2
d
ay
s
p
o
st
-t
ra
ns
fe
ct
io
n
w
er
e
al
so
tr
an
sf
er
re
d
o
nt
o
fr
es
h
B
H
K
-2
1
ce
lls
an
d
fu
rt
he
r
ap
p
lie
d
to
tw
o
m
o
re
p
as
sa
g
es
o
n
B
H
K
-2
1
ce
lls
.V
ira
lp
ro
te
in
ex
p
re
ss
io
n
w
as
fin
al
ly
d
et
ec
te
d
o
n
d
ay
1
af
te
r
th
e
se
co
nd
p
as
sa
g
e
b
y
IF
st
ai
ni
ng
.(
b
)
C
o
m
p
ar
is
o
n
o
f
th
e
hy
d
ro
p
ho
b
ic
ity
o
fP
V
-2
A
D
3
-H
,Q
V
-2
A
D
3
-H
an
d
P
V
-2
A
D
3
-H
-I
-3
C
iw
ith
th
ei
r
co
rr
es
p
o
nd
in
g
se
co
nd
-s
ite
m
ut
an
ts
us
in
g
K
yl
e-
D
o
o
lit
tle
al
g
o
rit
hm
(w
in
d
o
w
si
ze
1
1
).
S
eq
ue
nc
es
o
ft
he
C
-t
er
m
in
al
p
ar
t
o
fp
ro
te
in
C
o
fP
V
-2
A
D
3
-H
,Q
V
-2
A
D
3
-H
an
d
P
V
-2
A
D
3
-H
-I
-3
C
ia
re
sh
o
w
n
in
g
re
en
an
d
th
o
se
o
fP
V
-2
A
D
3
-H
-m
ut
1
,P
V
-2
A
D
3
-H
-m
ut
2
an
d
Q
V
-2
A
D
3
-
H
-m
ut
in
b
la
ck
.
A
cq
ui
re
d
m
ut
at
io
ns
ar
e
in
re
d
.
A
p
o
ss
ib
le
N
S
2
B
/3
cl
ea
va
g
e
si
te
is
un
d
er
lin
ed
in
re
d
.
TBEV mutants dependent on FMDV 3C protease
http://vir.sgmjournals.org 511
synthesis after infection. As expected, TBEV-2A exhibited a
delayed and reduced RNA replication (Fig. 8). Interest-
ingly, mutant PV-2AD3-mut1 also showed a delay in the
onset of RNA replication during the first 6 h post-
infection. Nevertheless, after the onset of RNA replication,
no further impairment in RNA synthesis was detectable.
Indeed, already 9 h post-infection, this mutant produced
as many RNA molecules as the WT-TBEV, which is in
good accordance with the results shown in Fig. 7. In
contrast, PV-2AD3-mut2 and QV-2AD3-mut produced
similar amounts of RNA copies (Fig. 8). Thus, the
reduction of foci size and infectivity of PV-2AD3-mut2
and QV-2AD3-mut does not appear to be the result of an
impaired RNA replication.
DISCUSSION
We show here that the production of infectious flaviviral
virions can be dependent on protein C cleavage by a
heterologous protease, the FMDV 3Cpro. Virion produc-
tion was enabled by providing the enzyme either in cis or in
trans from a TBEV replicon. Virion assembly was more
efficient when the 3C protease was provided in trans. Most
probably, in the cis construction, protein synthesis from
the 59 end of the TBEV genome was lowered by the
presence of the IRES element in the 39 non-coding region.
This has also been observed in bicistronic TBEV mutants
in which an IRES element controls the expression of the
structural proteins prM and E (Orlinger et al., 2006).
Cell-based antiviral assays in which the production of
infectious virions depends on cleavage by HCV NS3 pro-
tease have been reported (Filocamo et al., 1997; Hahm
et al., 1996; Lai et al., 2000). Our system is, however, the
first to enable the recovery of a non-infectious virus
through a second replicon expressing the required pro-
tease. To assess the genetic stability of this system, we
investigated how rapidly monocistronic full-length TBEV
mutants PV-2AD3-H and QV-2AD3-H would acquire
spontaneous mutations during passage on BHK-21 cells
in the absence of the 3Cpro. Similarly, we also investigated
the bicistronic PV-2AD3-H-I-3Ci construction that con-
tains an inactive 3Cpro as well as the monocistronic full-
length TBEV mutant PV-2AD3-H together with the TBEV
replicon expressing an inactive 3Cpro. Multiple amino acid
changes at the C–prM junction were observed in the PV-
2AD3-H and QV-2AD3-H mutants as well as in PV-2AD3-
H-I-3Ci but not in the PV-2AD3-H transfected with the
TBEV replicon expressing the inactive 3Cpro. This indicates
that the trans-complementation system is more stable than
the cis system.
The specific changes in the revertants all resulted from the
insertion of one nucleotide and the deletion of a second.
Throughout, an NS2B/3pro cleavage motif R-R*C was
introduced at an identical location in the 2AD3 region so
that cleavage at this sequence by NS2B/3pro should give rise
to a C-terminal extension of 14 aa in protein C in all three
revertants. Furthermore, in PV-2AD3-H, six amino acids
within the 2AD3 protein sequence were mutated, whereas
in QV-2AD3-H and PV-2AD3-H-3Ci, the insertion and
deletion led to the mutation of the same 22 aa, located in
both the C-terminal region of protein C and the 2AD3
protein sequence. The new amino acid sequences differed
only in the most C-terminal amino acid of the mutated
region (Fig. 5b and c).
Introduction of the mutations into TBEV-2AD3 confirmed
that they restored the production of infectious virus
progeny. In addition, protein C of all three mutants showed
a slower mobility on SDS-PAGE than the WT (Fig. 6),
strongly suggesting that cleavage was performed by NS2B/
3pro at the putative cleavage site.
Differences in the properties of the revertants were evident.
PV-2AD3-H-mut1 reached wild-type levels both in infec-
tivity and RNA synthesis and showed only a minor effect
on viral spread. However, a delay in the onset of early RNA
replication was detectable. The other mutants PV-2AD3-H-
mut2 and QV-2AD3-H-mut that bear the almost identical
22 aa change also grew to high titres, just 1 and 1.5 log
units lower than WT-TBEV, respectively. Both exhibited a
smaller foci size, even though their RNA replication was
similar to the WT-TBEV level.
The origin of these differences might be the more
hydrophilic character of the protein C extension of all
three revertants (compared with that of TBEV-2A), which
would favour both the infectivity and early RNA synthesis.
This agrees with our previous work on TBEV-2A,
indicating that a hydrophobic extension to protein C can
interfere with particle formation, viral spread and early
RNA replication (Schrauf et al., 2009). The different
behaviour of the revertants in the onset of early RNA
replication described here can be also attributed to the
Fig. 6. Analysis of structural-protein processing. Cells transfected
with WT or mutant RNAs were lysed 48 h post-transfection, and
proteins were detected by immunoblotting using a rabbit
polyclonal serum against the TBEV structural proteins. Positions
of proteins E, prM, C and C* as well as marker proteins in kDa are
marked.
S. Schrauf and others
512 Journal of General Virology 93
composition of the protein C extension. A comparison of
all three revertants and TBEV-2A reveals that the more
hydrophobic the extension of protein C, the lower the rate
of early RNA synthesis in general and the later the onset of
early RNA replication and/or unpackaging in particular.
The amino acid changes of mutants PV-2AD3-H-mut2 and
QV-2AD3-H-mut resulted in a more hydrophilic 2AD3
region than in the case of PV-2AD3-H-mut1. Consequently,
these two mutants have no impairment in the onset of
early RNA synthesis, in marked contrast to the 6 h delay of
PV-2AD3-H-mut1. TBEV-2A, however, which possesses an
extension of mainly hydrophobic amino acids showed both
a delay as well as a reduction in early RNA synthesis. Finally,
the observed difference between the revertants and TBEV-
2A also suggests that the re-establishment of a NS2B/3pro
cleavage in the C-terminal region of C is advantageous for
viral spread.
Despite these beneficial contributions, the more hydro-
philic character of the extension did not aid viral spread.
PV-2AD3-H-mut2 and QV-2AD3-H-mut, which carry
more hydrophilic amino acids in the 2AD3 region than
PV-2AD3-H-mut1, formed considerably smaller foci that
could be visualized only 3 days post-infection. In contrast,
the foci of PV-2AD3-H-mut1 were only marginally smaller
than those of the WT. The difference appears to lie in the
C-terminal part of protein C, where only PV-2AD3-H-
mut2 and QV-2AD3-H-mut have acquired additional
mutations. These mutations led to the loss of two basic
amino acids in the C-terminal part of protein C. Ma,
Dokland and their co-workers (Dokland et al., 2004; Ma
et al., 2004) have shown for dengue virus andWNV protein C
that protein C occurs as a dimer with the two C-terminal
helices forming a broad interface for interaction with RNA.
Therefore, the loss of positive charges close to the helix
may hinder correct dimer formation and/or RNA binding.
Given that the RNA production upon infection was at
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wild-type levels (Fig. 8), we can exclude a defect in
unpackaging or synthesis of RNA. In contrast, we propose
that the accumulation of protein C in the cytoplasm is
crucial (Fig. 6), indicating that the reduced infectivity of
PV-2AD3-H-mut2 or QV-2AD3-H-mut is caused by a
defect in formation and/or budding of the NC, thus
limiting viral spread. In contrast, the protein C of the PV-
2AD3-H-mut1 was not affected by the amino acid changes
and no accumulation of protein C in the cytoplasm
occurred (Fig. 6), indicating that budding was undisturbed.
Our results highlight therefore a previously undetected role
of the C terminus of protein C for budding of the NC and
the necessity of positive charges.
METHODS
Plasmids and cells. All TBEV constructs derive from the cDNA of
TBEV strain Neudoerfl (GenBank accession no. U27495) (Mandl
et al., 1997). BHK-21 (ATCC CCL10) cells were cultured as described
previously (Schrauf et al., 2008). Oligonucleotides are listed in
Supplementary Table S1 (available in JGV Online).
Full-length TBEV mutants. pTNd/59 (Schrauf et al., 2008) and all
derivatives of pTNd/59 contain the 59 one-third of the cDNA of TBEV
strain Neudoerfl genome. Infectious full-length RNA was generated
after in vitro ligation of the 59 cDNA clones with the 39 cDNA clone
pTNd/39 (Schrauf et al., 2008), which contains the 39 two-thirds of
the TBEV genome. Plasmid p2AD3/59 was constructed by deleting the
PGP motif at the C-terminal end of the FMDV-2A protein sequence
of TBEV-2A/59. For plasmid pPV-2AD3/59, the P4 (proline) and
the P3 positions (valine) of the 3Cpro cleavage site were introduced
upstream of lysine 94 of the TBEV protein C using the forward primer
P43-F, the reverse primer P43-R and p2A3D/59 as template. Plasmid
pPV-2A3D-H/59, containing the P4 and P3 positions of the 3Cpro
cleavage site as well as the heparan sulphate mutation E122G in
protein E, was generated using the forward primer E122G-F, the
reverse primer E122G-R and pPV-2A3D/59 as template. Plasmid
pQV-2A3D-H/59, containing valine instead of proline at the P4
position of the 3Cpro cleavage site, was created using the forward
primer PQ-F, the reverse primer PQ-R and pPV-2A3D-H/59 as
template.
Plasmid pTNd/c contains a full-length genomic cDNA of the WT
TBEV strain Neudoerfl. TBEV-2A contains a functional FMDV-2A
sequence that replaces the NS2B/3 cleavage site between protein C
and prM. RNA of TBEV mutants with resuscitating mutations in the
2AD3 region was isolated, reverse transcribed and cloned into the
pTNd/c cDNA using restriction sites for SalI and SnaBI; the cDNAs
have no heparan sulphate mutation.
TBEV replicons. Replicons DME-I-3C and DME-I-3Ci are deriva-
tives of clone DME–eGFP (Gehrke et al., 2005), expressing the eGFP
under the control of the ECMV IRES. The replicon DME-I-3C was
created by a three-step PCR strategy. PCR-I was performed using the
forward primer AvrII-F, the reverse primer IRES-3C-R and plasmid
ME–DeGFP as template. PCR-II amplified the 3Cpro with the forward
primer IRES-3C-F, the reverse primer 3C-AgeI-R and plasmid pET-
3C (provided by Francois Maree, Onderstepoort, South Africa,
containing the FMDV 3C sequence of strain O/SAR/19/00) as
template. PCR-III was then performed with primers AvrII-F and
3C-AgeI-R using PCR products I and II as template. Then, the AvrII–
AgeI fragment of DME–eGFP was replaced by the AvrII and AgeI
restricted PCR product III to generate DME-I-3C. Replicon DME-I-
3Ci, containing a cysteine-to-alanine mutation at position 163 of the
3C protease, was constructed in a similar way as described above, with
the primer combinations AvrII-F and C163A-R for PCR-I and
C163A-F and AgeI-R for PCR-II. As template, DME-I-3C was used.
Plasmid DME-I-3C was amplified in Escherichia coli Copy Cutter
EPI400 (Epicentre) E. coli HB101 was used for all other plasmids.
RNA transcription and transfection. Transcription of RNA in vitro
and transfection into BHK-21 cells by electroporation were as
described previously (Mandl et al., 1997; Schrauf et al., 2008).
Detection of viral proteins. Viral protein expression was examined
by IF staining and Western blotting. For IF, transfected BHK-21 cells
were disseminated into 24-well tissue culture plates containing
microscope coverslips and permeabilized by acetone-methanol
fixation (1 : 1) 1 day post-transfection. Expression of the structural
proteins C, prM and E and the non-structural protein NS1 was
visualized by successive incubation with a rabbit polyclonal anti-
TBEV serum predominantly recognizing protein E and protein
NS1 and fluorescein-isothiocyanate-conjugated anti-rabbit antibody
(Jackson Immune Research Laboratory). For passaging experiments,
supernatants from transfected BHK-21 cells seeded in 25 cm2 tissue
culture flasks were transferred onto fresh BHK-21 cells 1 day post-
transfection and viral protein expression was analysed as described
above 1 day post-infection. For the selection of resuscitating muta-
tions, supernatants from transfected cell cultures were applied to fresh
cells 2 days post-electroporation and, after a second round of passage,
viral protein expression determined.
Formation of the structural proteins prM and E was monitored by
immunoblotting (Schrauf et al., 2008).
Virus stock preparation. To generate virus stocks, BHK-21 cells
were electroporated with RNAs of WT-TBEV, TBEV-2A, PV-2AD3-
mut1, PV-2AD3-mut2 and QV-2AD3-mut, respectively. Supernatants
were harvested 48 h post-electroporation. RNA was isolated from
these stocks, followed by reverse transcription. Constructs were
confirmed by sequencing. Titre and focus morphology were
determined by focus assay.
Multistep growth curves. BHK-21 monolayers grown in six-well
plates were infected with stock preparations of respective viruses at a
m.o.i of 0.01. Aliquots of supernatants were collected at various time
points and infectious particles were quantified by focus assay.
Focus assay. To quantify the production of infectious virus particles,
an immunochemical focus assay was employed (Schrauf et al., 2009).
RNA replication. Intracellular RNA replication after infection was
determined as described previously (Schrauf et al., 2009).
Protein sequence analysis. Hydrophobicity plots were done using
the DNASTAR programme PROTEAN (Kyle-doolitle scale, window size
11).
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Abstract 
 The replication of tick-borne encephalitis virus (TBEV), like that of all flaviviruses, is 
absolutely dependent on proteolytic processing. Production of the mature proteins C and prM 
from their common precursor requires the activity of the viral NS2B/3 protease (NS2B/3pro) at 
the C-terminus of protein C and the host signal peptidase I (SPaseI) at the N-terminus of 
protein prM. Recently, we have shown in cell culture that the cleavage of protein C and the 
subsequent production of TBEV particles can be made dependent on the activity of the foot-
and-mouth disease virus 3C protease, but not on the activity of the HIV-1 protease (HIV-1pro) 
(S. Schrauf et al., 2012 and personal communication). To investigate this failure, we developed 
an in vitro cleavage assay to assess the two cleavage reactions performed on the C-prM 
precursor. Accordingly, a recombinant modular NS2B/3pro, consisting of the protease domain of 
NS3 linked to the core-domain of cofactor NS2B, was expressed in E. coli and purified to 
homogeneity. This enzyme could cleave a C-prM protein synthesised in rabbit reticulocyte 
lysates. However, cleavage was only specific when protein synthesis was performed in the 
presence of canine pancreatic microsomal membranes and required the prevention of signal 
peptidase I (SPaseI) activity by lengthening the h-region of the signal peptide. Substitution of 
the NS2B/3pro cleavage motif in C-prM by a HIV-1pro motif inhibited NS2B/3pro processing in the 
presence of microsomal membranes but allowed cleavage by HIV-1pro at the C-prM junction. 
However, a second cleavage site for HIV-1pro was observed in the prM part in both the 
presence and absence of microsomal membranes. This indicates that the eight amino acid 
HIV-1pro cleavage site disturbed the correct membrane insertion of the C-prM precursor and 
provides an explanation why C-prM cleavage and TBEV particle production could not be made 
dependent on HIV-1pro activity in cell culture.  
Introduction  
Tick-borne encephalitis virus (TBEV), a member of the family of Flaviviridae in the 
genus Flavivirus (Lindenbach et al., 2007) is a small (~50 nm) enveloped virus with a single 
stranded, positive sense RNA genome. In addition to the lipid envelope and the RNA, three 
structural proteins (capsid (C), membrane (M, derived from a precursor prM) and envelope (E)) 
are present in the virion. The genetic information in the viral RNA is expressed as a single 
polyprotein that meanders in and out of the endoplasmic reticulum (ER) membrane. The 
structural proteins are located in the amino-terminal part of the polyprotein; the rest of the 
polyprotein comprises the non-structural proteins NS1, NS2A, NS2B, NS3, NS4A, NS4B, and 
NS5 (Lindenbach et al., 2007). NS2B and NS3 (designated here NS2B/3pro) comprise the viral 
protease that is required for polyprotein processing, along with furin and signal peptidase I 
(SPaseI), two host cell proteases. These cleavages occur co- and post-translationally. In 
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addition, during translation and processing, the surface proteins prM and E are glycosylated in 
the lumen of the endoplasmic reticulum (ER). The production of these structural proteins is vital 
as protein C is the initiator molecule for viral assembly; multiple copies of this protein 
encapsidate a newly synthesised RNA molecule to produce the nucleocapsid (NC). 
Furthermore, prM is required to ensure that protein E is manufactured in a viable conformation. 
Correctly processed prM and E are added to the growing particle by budding of the NC through 
the ER. The resulting immature particles cross the trans-Golgi network (TGN), permitting furin 
cleavage of prM; this reaction transforms the immature particles into infectious virions (Stadler 
et al., 1997).  
Processing is thus a prerequisite for the assembly of the TBEV particle; not surprisingly, 
the two processes are closely co-ordinated (Lobigs, 1993). For instance, the C-terminus of the 
protein C contains an internal hydrophobic signal sequence responsible for translocating the 
prM protein into the lumen of the ER. On the cytosolic side of the ER membrane, protein C is 
cleaved off the signal sequence by NS2B/3pro (Amberg et al., 1994; Yamshchikov and 
Compans, 1994). This cleavage is a prerequisite to allow the host cell SPaseI cleavage at the 
signal sequence on the luminal side of the ER membrane to generate the N-terminus of protein 
prM. Initiation of virion assembly has been proposed to depend upon the timing of these 
cleavage events at the termini of the signal sequence separating proteins C and prM (Amberg 
and Rice, 1999; Lee et al., 2000; Lobigs and Lee, 2004; Stocks and Lobigs, 1998). Protein prM 
is in its turn a prerequisite to ensure correct synthesis and transport of protein E (Konishi and 
Mason, 1993; Lorenz et al., 2002). 
In TBEV, investigation of the cleavage by NS2B/3pro in the C-terminal region of protein C 
is complicated by the presence of two potential cleavage sites (KR*G and RR*G, underlined in 
Fig. 2 (Mandl et al., 1991)). Schrauf et al. (Schrauf et al., 2009) showed that, in vivo, the 
downstream cleavage site is used and that the upstream cleavage motif cannot be accepted 
when the downstream cleavage motif had been removed by mutation.  
Schrauf et al. (Schrauf et al., 2009) showed further that, in the absence of the 
downstream NS2B/3pro cleavage site, the C-terminus of protein C could be released from the 
polypeptide chain by the introduction of the foot-and-mouth disease virus (FMDV) 2A 
sequence. The presence of the sequence Asn-Pro-Gly-Pro at the C-terminus of this 20 amino 
acid protein causes the ribosome to pause, release the first protein and then continue 
translation of the mRNA. In contrast, upon removal of the residues Pro-Gly-Pro from the 20 
amino acid sequence, the separation of C and prM was inhibited, leading to a replication 
deficient virus. Virion production could be rescued by the introduction of an FMDV 3Cpro 
cleavage site at the N-terminus of the 2A sequence and the expression of the 3Cpro either in cis 
from a second ORF or in trans from a TBEV replicon (Schrauf et al., 2012). However, we were 
unable to achieve success in such a system with the HIV-1pro (Schrauf et al., unpublished). We 
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reasoned that this failure might be due to the presence of additional cleavage site(s) for the 
HIV-1pro in the C-prM region. To investigate this idea, we set out to establish an in vitro assay 
system for proteolytic cleavage in the C-terminal region of protein C. 
 
Material and methods 
Oligonucleotides and plasmids 
 Oligonucleotide sequences can be found in supplementary table 1. Constructs encoding 
TBEV European subtype strain Neudörfl (EMBL: U27495) were derived from pBR-TBEV-∆ME-
EGFP (kind gift of Dr. P. Schlick). Plasmids coding for the co-factor and the protease were 
constructed in two steps. First, the hydrophilic cofactor region of NS2B (Fig. 1A, corresponding 
to amino acids 1404 to 1453 of the TBEV polyprotein (UniProt: P14336) was amplified by 
primers NS2B-f and NS2B-r-3´linker. These primers, introducing an NcoI restriction site at the 
5´ end and the first half of the synthetic linker containing an XmaI recognition sequence at the 
3´ end, were used to clone the fragment into pCite-A1, designated as pCite-A1-NS2B. Then, a 
fragment encoding the 190 N-terminal residues of NS3 (Fig. 1B), the protease domain (UniProt: 
P14336, residues 1490 to 1679) was amplified with primers 5´-Linker-NS3-F and NS3-R-6xHis. 
Thereby, the second half of the synthetic linker containing an XmaI recognition site was 
introduced at the 5´end of the protease region. Furthermore, six histidine codons and a BamHI 
site were added to the 3´end. These enzymes were used to ligate the protease domain to 
pCite-A1-NS2B, finally named pCite-A1-NS2B/3, coding for the tethered NS2B/3 protease (Fig. 
2A).  
NS2B/3 S135A with alanine substitutions at S135 in the catalytic triad of NS3 were 
made by site-directed mutagenesis with primers NS3 S135A-f and NS3 S135A-r. 
To generate the stabilised proteases with the new linker GGGGSGGGG, a cleavage 
site for BglII was introduced downstream of the linker with primers NS3-BglI-f and NS3-BglI-r. 
Cassettes coding for the desired mutations K90A and R93A of NS2B as well as the new linker 
were designed and introduced by use of the BglII and XhoI. The mutation G to A in the linker 
region of construction NS2B/3 R93A occurred serendipitously during mutagenesis. As the 
ensuing protease proved to be stable and active, it was used in all subsequent experiments. 
For expression in E. coli, sequences coding for the desired tethered proteases were 
cloned from pCite-A1-NS2B/3 into the expression vector pET11d by use of NcoI and BamHI. 
To generate the plasmids coding for the substrates (Fig 2B and 2C), plasmid pTNd/5 
which contains the 5´part of the genome of TBEV European subtype strain Neudörfl, was used 
as template (kind gift of Dr. R. Kofler). Using primers C-prM-f and C-prM-r, we produced PCR 
fragments encoding the capsid protein, transmembrane region and pre-membrane protein prM. 
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Thus, C-prM corresponds to residue 1 to 280 of the TBEV polyprotein. The plasmid was named 
pCITE-C-prM. 
To generate pCITE-C-2A∆3-prM and pCite-C-HIV-prM, we used plasmid pBR-C-2A∆3-
prM and pBR-C-HIV-prM, both kind gifts of Dr. S. Schrauf. By use of AgeI and MluI, we isolated 
the desired fragment and cloned it into pCite-C-prM using the same cleavage sites.  
In order to inhibit signal peptidase cleavage, nine leucine residues were introduced into 
the transmembrane regions of substrates by use of primers TM-9L-f and TM-9L-r. 
 
In vitro transcription and translation 
 All pCITE plasmids were linearised with BamHI. In vitro transcription with T7 RNA 
polymerase and in vitro translation were as described in Schlick et al. (Schlick and Skern, 
2002). In vitro translation reactions (typically 20 µl) contained 70% RRL (Promega), 20 µCi of 
35S-methionine (1000 Ci/mmol, American Research Company) and amino acids (except 
methionine) at 20 µM. After pre-incubation for 1 min at 30°C, translation was started by addition 
of RNA. The reaction was stopped at designated time points by immediate transfer to ice and 
addition of unlabelled methionine and cysteine to a final concentration of 2mM. Where 
indicated, translation reactions were supplemented with 4 to 8% pancreatic microsomal 
membranes (Promega). 
 
Protease assay 
 For self-cleavage reactions, translation products with or without microsomal membranes 
were incubated in assay buffer (20mM Tris/HCl, pH 7, 50 mM NaCl) at 30°C and quenched by 
addition of an SDS-PAGE loading buffer to a final concentration of 2% SDS.  
 Trans-cleavage reactions were performed at 30°C in a final volume of 10µl containing 
substrate and purified NS2B/3pro at the indicated final concentrations and assay buffer. After the 
indicated times, the reaction was stopped by addition of SDS sample buffer. 
 
Electrophoresis and immunoblotting 
 The polyacrylamide gel electrophoresis system of Dasso und Jackson (Dasso and 
Jackson, 1989), containing 15% polyacrylamide, was used to separate proteins. 35S-containing 
proteins were detected by fluorography. 
 
Expression and purification 
 The plasmids pET 11d-NS2B/3, pET 11d-NS2B/3 S135A, pEt11d-NS2B/3 R50A G59A 
were used for high-level, inducible expression of hexa-histidine-tagged recombinant proteins. 
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Cultures of E. coli strain BL21(DE3)pLysS transformed with the expression plasmids were 
grown in 10 ml of LB medium containing 34 µg/ml chloramphenicol and ampicillin at 37°C 
overnight. This overnight culture was diluted 1:100 in fresh LB medium containing 
chloramphenicol and ampicillin at the concentrations stated above and incubated at 37°C, 225 
rpm until an OD600 of 0.5 to 0.6 had been reached. The expression of the recombinant proteins 
was induced by addition of isopropyl-β-D-thiogalactopyranose (IPTG) to a final concentration of 
0.1 mM. Cultures were incubated for additional 4 hours, and cells were harvested by 
centrifugation. Cell pellets were resuspended in 30 ml resuspension buffer containing 50mM 
Tris-HCl, 50mM NaCl, pH 8 and lysed with a Bandelin Sonoplus sonicator (4 cycles, 40%, 30 
seconds and once continuous for 30 seconds) and centrifuged at 15,000 rpm for 30 min at 4° 
C. The supernatant was loaded onto a 5 ml HiTrap chelating column (GE Healthcare) loaded 
with Nickel and pre-equilibrated with lysis buffer. The protein was eluted with a linear gradient 
of 0 to 500 mM imidazole in lysis buffer. Fractions containing NS2B-NS3 proteins, determined 
by 12.5% SDS-PAGE, were pooled, concentrated using Amicon Ultra-4 Centrifugal filter Device 
10kDa cut-off (Millipore). Subsequently, it was loaded on to a HiLoad TM 26/60 Superdex 75 
column (GE Healthcare) equilibrated with resuspension buffer and run according to the 
manufacturer´s instructions. Fractions were again analysed by SDS-PAGE. Aliquots were 
stored until use at -80° C. 
 
Expression and purification of the HIV-1pro 
 Penta-stabilised HIV-1pro Q7K, L33I, L63I C67 C95A was a kind gift of Dr. J. Tözsér 
(Louis et al., 1999). Briefly, the protease was expressed in E. coli and refolded by dialysis 
against 25mM formic acid for 2 hours and then against 100mM Na-acetate-trihydrate, 1mM 
DTT, 1mM EDTA, 10% glycerol and 0,03% Triton X-100, pH 5 five times for 2 hours. This 
buffer was also used in HIV-1pro trans-cleavage experiments. 
 
Results 
Generation of an active TBEV NS2B/3pro 
 The proteolytic domain of the multifunctional flaviviral NS3 protein serine protease 
resides in the amino-terminal domain. The protein folds into two ß-barrels with the hydrophilic 
core being stabilised by the co-factor NS2B (Erbel et al., 2006). Without the NS2B domain, the 
NS3 protease is proteolytically inert. It has been shown by Leung et al. (Leung et al., 2001) that 
the cofactor activity of the NS2B core region is comparable to that of the entire NS2B 
sequence. This knowledge allowed single chain NS2B/3pro to be generated by genetically 
fusing the NS2B core region to the NS3 protease domain by a short linker region. Indeed, 
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NS2B/3pro of several flaviviruses have been expressed in this way (Bessaud et al., 2005; Leung 
et al., 2001; Nall et al., 2004; Shiryaev et al., 2006; Yusof et al., 2000). To generate a similar 
construction for TBEV, the pertinent regions of NS2B and NS3 in the TBEV polyprotein were 
analysed by sequence alignment with WNV (Fig. 1) and related flaviviruses (data not shown). 
Residues 46 to 94 of TBEV NS2B (in green in Fig. 1A) and residues 1 to 190 (in red in Fig. 1B) 
of NS3 were identified as the central hydrophilic co-factor region of NS2B and the protease 
domain of NS3, respectively. These regions were amplified by PCR as indicated in Methods 
and linked by a DNA sequence encoding the flexible linker indicated in Fig. 2A. To prevent the 
loss of the NS2B activating peptide through autocatalytic cleavage, we attempted to ensure that 
no cleavage site for the NS3 protease was present in the flexible linker. A C-terminal hexa-
histidine tag was introduced at the C-terminus for purification. A similar construct containing the 
inactivating mutation S135A was also prepared. Both wild-type and the inactivated mutant 
could be produced either by in vitro transcription and translation assay in rabbit reticulocyte 
lysates (RRL) or by expression in E. coli. 
 To test whether the NS2B/3 hybrid protein was indeed stable, the NS2B/3pro and 
NS2B/3pro S135A RNAs were translated in RRL in the presence of 35S methionine for 30 min at 
30°C followed by addition of unlabelled methionine and incubation at 30°C for the indicated 
times. Synthesised proteins were separated by SDS-PAGE and detected by fluorography. Both 
NS2B/3pro and NS2B/3pro S135A RNAs were translated into a protein of 33 kDa, slightly higher 
than the calculated Mr of 28 kDa. During the incubation of the active protease, the 33 kDa band 
slowly disappeared overnight and was replaced by bands of apparent molecular weight 28 kDa 
and 12 kDa. However, as the smaller band was actually running with the buffer front of the gel, 
its molecular weight cannot be given with any confidence. In contrast, the 33 kDa band of the 
inactive NS2B/3pro S135A remained stable (Fig. 3), suggesting that autolysis of the active 
protease was responsible for the conversion of the 33 kDa species into the two smaller ones.  
Similar results were obtained using the bacterially expressed NS2B/3pro (data not 
shown). Mass spectroscopy of the purified 28 kDa band from SDS-PAGE revealed that it 
lacked the N-terminal 47 amino acids of the NS2B sequence. Thus, despite the lack of a 
corresponding cleavage site, the active NS2B/3pro was still able to perform autolysis between 
residues K90 and E91 (Fig. 2 and 3), giving rise to fragments of a calculated Mr of 22 and 6 
kDa, respectively. To prevent such autolysis, we constructed two modified NS2B/3 proteins in 
which either one (R93A) or two (K90A R93A) basic residues at the C-terminus of 2B were 
replaced with alanine (Fig. 2A). In addition, the linker sequences were also modified to more 
closely resemble that used in other flaviviral NS2B/3 constructs (Fig. 2A). RNA from the 
resulting constructs NS2B/3pro R93A and NS2B/3pro K90A R93A was translated in RRLs; both 
synthesised proteins were stable over the time-course of the experiment (Fig. 3). NS2B/3pro 
R93A was selected for use in all subsequent experiments. 
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In Vitro Processing of the Structural Protein Precursor C-prM 
The precursor (C-prM) of C and prM is connected by a short hydrophobic domain that 
spans the membrane of the ER. C is cleaved into its mature form by the NS2B/3pro at the 
cytosolic side whereas the SPaseI cleaves prM to its mature form in the ER (Fig. 2B and 2C). 
SPaseI only gains access to its cleavage site once NS2B/3pro has cleaved at the C-terminus of 
protein C. To investigate this cleavage reaction in vitro, we incubated purified recombinant 
NS2B/3pro R93A with C-prM synthesised in RRL. Control experiments were performed with 
buffer or with recombinant inactive NS2B/3pro S135A (final concentration 1 µg/µl). Proteins 
were separated by SDS-PAGE and detected by fluorography. 
A single specific band corresponding to unprocessed C-prM running at 35 kDa was 
detected when the substrate was incubated with buffer or inactive NS2B/3pro (Fig. 4A, lanes 2 
to 4 and data not shown). When incubated with active NS2B/3pro at a final concentration of 
1µg/µl (Fig. 4A, lane 5 to 8), the substrate was converted into two bands running at 27 kDa, 
corresponding to prM* (prM plus amino-terminal transmembrane region), and about 10 kDa, 
corresponding to protein C. We tested several assay conditions to optimise the cleavage 
efficiency but were not able to find conditions in which amounts of protein less than 1 µg/µl led 
to cleavage. Thus, the cleavage efficiency of the purified protease remained rather low in 
comparison with recombinant proteases from related viruses (Bera et al., 2007; Chappell et al., 
2008; Shiryaev et al., 2007).  
 
NS2B/3pro cleavage of prM in vitro does not depend on the presence of its cleavage site 
The canonical NS2B/3pro recognition site in the C-terminal region of protein C of TBEV 
was shown previously to be at R-R*S ((Schrauf et al., 2008); Fig. 2A). To test whether the 
cleavage of C-prM by NS2B/3pro was dependent on the presence of its cleavage site, we 
generated a C-prM mutant (C-2A∆3-prM) in which the downstream NS2B/3pro cleavage site 
was replaced by a version of the 2A sequence of foot and mouth disease virus (FMDV) lacking 
the characteristic Pro-Gly-Pro motif at its C-terminus (see Fig. 2). This form is unable to allow 
the ribosomes to skip the formation of a peptide bond so that protein C cannot be released from 
the polyprotein (Donnelly et al., 2001). A TBEV mutant bearing this truncated 2A (C-2A∆3-prM) 
was replication deficient, as protein C could not be processed by the NS2B/3pro (Schrauf et al., 
2009). This provides further evidence that the upstream cleavage site is not used. 
Nevertheless, in this in vitro system described here, we observed, in the absence of the 
downstream cleavage site at the C-terminus of protein C, cleavage of the C-2A∆3-prM with 
purified NS2B/3pro (Fig. 4B, lane 3). The most likely interpretation is that the upstream cleavage 
was substituting for the downstream site. 
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It should be noted that, despite repeated attempts, we were not able to detect the 
cleavage product for protein C. We interpret this failure to mean that the modified protein C 
containing all or part of the 2A protein of FMDV is unstable in RRLs. We have observed this 
phenomena previously when expressing other viral proteins in this system (Sousa et al., 2006). 
 
Signal peptidase cleavage of C-prM in the presence of microsomal membranes occurs in 
the absence of NS2B/3pro cleavage 
We postulated that the specificity of the NS2B/3pro reaction could be increased by the 
addition of canine pancreatic microsomal membranes (subsequently referred to as 
membranes) to allow the signal peptide that separates the two proteins to insert into a 
membrane. Upon translation of C-prM in the presence of the above-mentioned membranes for 
30 min, a decrease in its electrophoretic mobility could clearly be seen after a further 60 min of 
incubation at 30°C (Fig 5A, compare lane 2 with lane 3), suggesting that N-glycosylation had 
occurred at residue Asp 144 of prM (Fig. 5A, lane 3). After 120 min, however, the amount of the 
C-prM species had decreased; instead, a new band had appeared at 28 kDa, corresponding to 
glycosylated prM lacking the trans-membrane region (Fig. 5A, lane 4).  
The most likely explanation for the above result is that the membrane bound signal 
peptidase (SPaseI) has processed its luminal cleavage site in the absence of the viral protease. 
According to previous studies, however, the SPaseI cleavage should not occur until the 
NS2B/3pro has performed processing at the C-terminus of protein C (Lobigs, 1993; Lobigs and 
Lee, 2004; Stocks and Lobigs, 1995). As we wished primarily to investigate NS2B/3pro 
cleavage, we looked for an approach to inhibit the SPaseI reaction whilst permitting the 
cleavage by NS2B/3pro. To this end, we first used a known inhibitor of SPaseI, N-
methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl ketone (Lundin et al., 2008; Nilsson et al., 
2002). Indeed, this compound, at concentrations of 750 µM or higher, did inhibit the proposed 
SPaseI cleavage reaction (data not shown). However, this concentration also inhibited the 
activity of NS2B/3pro (data not shown), leading to the abandonment of this approach. 
We therefore took an alternative approach to eliminate SPaseI cleavage. Signal 
peptides have been shown to possess a common structure, namely a short, positively charged 
amino-terminal n-region, a central hydrophobic h-region (blue in Fig. 2B and 2C) and a polar, 
mostly uncharged c-region containing the signal peptidase cleavage site. In addition to certain 
other differences, one appreciable difference between cleaved signal peptides and non-cleaved 
signal anchors is the length of the h-region. Consequently, it is possible to convert a signal 
peptide into a signal anchor by lengthening its h-region (Nilsson 1994). To this end, we 
introduced a stretch of nine leucine residues into the h-region of the signal peptide between C 
and prM (Fig. 2C). RNA from this construct, termed C-9L-prM, was then incubated in RRLs in 
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the presence of microsomal membranes and the stability of the translated protein examined. 
Figure 5B shows that the protein remained intact in both the absence (lanes 2 and 3) and 
presence of membranes (lanes 7 and 8), indicating that extension of the h-region conveyed 
resistance to SPaseI cleavage.  
It is worth noting that, in this experiment, the glycosylation was complete during the 
translation phase of the reaction (compare Fig 5A lane 2 with Fig 5B lane 7) and that there was 
hardly any detectable difference between the protein in the glycosylated and non-glycosylated 
form (compare left and right panels of Fig. 5B). We postulate that the presence of the nine 
leucine residues is the reason for these observations. 
 
NS2B/3pro shows higher activity and specificity in the presence of microsomal 
membranes 
Having generated a form of C-prM that was resistant to cleavage by SPaseI, we could 
now examine its ability to act as substrate for NS2B/3pro. Initial control experiments in the 
absence of microsomal membranes revealed that C-prM and C-9L-prM were processed equally 
with respect to extent and position of cleavage (data not shown). We therefore incubated C-9L-
prM that had been translated in the absence or presence of microsomal membranes with 
different concentrations of NS2B/3pro. Interestingly, the concentration of NS2B/3pro could be 
reduced by 10 to 20-fold (compare Fig. 5B lanes 4 and 5 with lanes 9 and 10) when 
microsomal membranes were used. NS2B/3pro at a final concentration of 500 ng/µl (Fig. 5B, 
lane 4) was required to cleave C-9L-prM in the absence of membranes, whereas 25 ng/µl (Fig. 
5B, lane 10) were sufficient to obtain cleavage of this substrate when membranes were used.  
To confirm that the NS2B/3pro enzyme was indeed recognising the correct cleavage site, 
we designed a C-9L-prM mutant in which the downstream NS2B/3pro cleavage site was 
replaced by a cleavage site of the HIV-1pro (C-HIV-9L-prM). Fig. 6 (lanes 4 and 5) shows that 
the protein is not cleaved by NS2B/3pro in the presence of membranes, even though the 
upstream cleavage site was still available. However, once again cleavage was observed in the 
absence of membranes (Fig. 6, lane 8).  
Thus, we concluded from the above set of experiments that the NS2B/3pro was indeed 
recognising its true cleavage site but only in the presence of membranes. 
 
The cleavage between C and prM can be performed by HIV-1pro 
 The presence of the HIV-1pro cleavage site in C-HIV-9L-M allowed us to investigate 
whether C-HIV-9L-prM was cleaved by HIV-1pro in the presence or absence of membranes. As 
a control, we used the construction C-9L-prM lacking the HIV-1pro cleavage site. In the absence 
of microsomal membranes, both constructs were processed by the HIV-1pro (Fig. 7A, lane 2 to 
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5), showing a similar pattern of two cleavage products of about 28 kDa and 20 kDa. The 28 
kDa band presumably arises through cleavage at the C-prM junction to give prM*, whereas the 
20 kDa band indicates cleavage at a position within protein C or prM. To verify that HIV-1pro is 
responsible for the cleavages, we added increasing concentrations of pepstatin, a known HIV-
1pro inhibitor (Wondrak et al., 1991). Figure 7B shows a concentration dependent inhibition of 
cleavage, indicating that the cleavage is indeed due to HIV-1pro processing. 
 Next we investigated HIV-1pro cleavage in the presence of microsomal membranes (Fig 
7A, lanes 6 to 8). Cleavage of the C-9L-prM construct was no longer observed (upper panel); 
however, with the C-HIV-9L-prM construct, the same cleavage products were observed as in 
the absence of membranes (lower panel). Thus, the presence of the membranes eliminated the 
cleavage of the C-prM construct lacking the HIV-1pro site, indicating that the protein was 
correctly inserted in the membrane. In addition, the cleavage products obtained with the C-HIV-
9L-prM indicate that correct processing at the HIV-1pro sequence was occurring, but suggested 
that a second cleavage site was present within the prM protein that was still accessible even in 
the presence of membranes. Nevertheless, this experiment shows clearly that it is possible, at 
least in vitro, to make the cleavage between proteins C and prM dependent on HIV-1pro. 
 
Discussion 
We present here a system in which the cleavage in the C-terminal region of protein C of 
TBEV can be specifically performed by purified recombinant viral NS2B/3 protease. Such 
cleavage required the presence of microsomal membranes to prevent non-specific proteolysis 
by the NS2B/3pro as well as introduction of nine leucine residues at the C-terminus of the 
transmembrane segment of protein C to prevent incorrect SPaseI cleavage. Cleavage of the 
protein C-9L-prM in the presence of membranes was efficient and specific, requiring only 25 
ng/µl to initiate cleavage. This NS2B/3pro cleavage could be prevented by the replacement of 
the NS2B/3pro cleavage site by a sequence from the FMDV 2A protein and thus demonstrated 
the specificity of cleavage, even though the putative upstream cleavage site in the C-terminal 
region of protein C was still present. The replacement of the NS2B/3pro cleavage site by that of 
the HIV-1pro cleavage site also prevented NS2B/3pro cleavage, further demonstrating the 
specificity of the reaction. The cleavage between C and prM could now be carried out by the 
HIV-1pro. However, a second cleavage was observed with the HIV-1pro. This may explain why it 
was not possible to make a TBEV that was dependent on cleavage with HIV-1pro as was the 
case for FMDV 3Cpro (Schrauf et al., 2012). 
To establish this system, a number of difficulties had to be overcome. Firstly, the 
modular NS2B/3 protein that we constructed was capable of undergoing autocatalytic cleavage, 
even in the absence of a dibasic sequence in the proximity of the linker. This reaction could be 
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prevented by the substitution of an arginine residue (R93) two amino acids upstream of the 
synthetic linker. This suggests that the presence of this basic residue, coupled with the 
proximity of the linker to the active site, allowed slow autoproteolytic cleavage to take place on 
a non-canonical cleavage sequence. 
This recombinant NS2B/3pro was purified to homogeneity and was able to cleave 
specifically in the C-terminal region of protein C, provided that translation took place in the 
presence of microsomal membranes and that SPaseI cleavage had been prevented by 
extension of the trans-membrane helix. This is in contrast to experiments that examined the 
cleavage of West Nile virus C-prM using infected cells as a source of the active WNV NS2B/3pro 
(Yamshchikov and Compans, 1994) and suggests a fundamental difference in the cleavage of 
the two viral polyproteins of WNV and TBEV.  
 Substitution of the NS2B/3pro cleavage motif in C-prM by of HIV-1pro allowed us to 
examine cleavage of C-HIV-9L-prM by the HIV-1pro in the presence of membranes. In addition 
to a band corresponding to prM*, indicating cleavage at the HIV-1pro sequence, an additional 
cleavage product with a size of about 20 kDa was observed. Where might the additional       
HIV-1pro cleavage sequence be located? Sequence analysis via an online HIV-1pro cleavage site 
prediction program (Chou, 1996; Chou et al., 1993; Shen and Chou, 2008) revealed a 
TVIR/AEGK motif spanning amino acids 134 to 143 with a high probability of cleavage by     
HIV-1pro. Cleavage at this site in prM would result in the formation of two bands of 20 and 6 
kDa, respectively, in good agreement with the observed 20 kDa band; the 6 kDa product would 
not be retained on the polyacrylamide gel. However, this site of the prM protein should be 
inside the membrane vesicles and not available for the protease. In contrast, the construction 
C-9L-prM without an HIV-1pro site was not cleaved by HIV-1pro in the presence of membranes. 
This implies that there is a difference in the orientation of the two proteins in the membrane that 
can only derive from the presence of the HIV-1pro cleavage site in the C-terminal region of 
protein C. This mis-orientation of the polyprotein containing the HIV-1pro cleavage site may 
explain why it was not possible to obtain virions when we tried to make the C-prM cleavage 
dependent on the HIV-1pro in cell culture using a bi-cistronic virus (Schrauf et al, unpublished). 
As the cleavage at the C-terminus was possible with the FMDV 3Cpro (Schrauf et al., 2012), the 
failure with the HIV-1pro must lie with this enzyme and/or with its cleavage site and not with the 
system per se. 
 This system will allow us to adjust the cleavage site of HIV-1pro to prevent the cryptic 
cleavage and mis-orientation and thus to obtain a higher chance of constructing a TBEV that is 
dependent on the activity of the HIV-1pro. In addition, this system may also serve as a model to 
examine the orientation of the transmembrane anchor of the TBEV protein C and the 
requirements for correct SPaseI processing. 
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Figures 
Figure 1 
 
Fig. 1. Alignment of tick-borne encephalitis virus (TBEV) and West Nile virus (WNV) amino acid 
sequences. (A) Complete sequences of NS2B. A conserved region involved in the formation of the active 
site in WNV is underlined. (B) N-terminal portions of NS3. Catalytic triad residues (His 54, Asp 78 and 
Ser 138) are indicated in blue. The parts of NS2B and NS3 used for constructing the recombinant TBEV 
NS2B/3 are green and red, respectively.  
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Figure 2 
 
Fig. 2. (A) Variants of recombinant proteases. The 48 amino acid residue-long, central portion of NS2B 
was linked with the NS3
pro
 sequence via a GASPGGSGA or GGGGSGGGAG linker, respectively. All 
protease constructs were C-terminally tagged with a (his)x6 tag. (B) Schematic diagram of the TBEV 
polyprotein with cleavage sites for the viral protease (black arrowhead), host signal peptidase I (blue 
arrowhead) and furin (diamond). (C) Variants of substrates used in this study. Schematic drawing of the 
C-terminal region of the capsid protein and the signal sequence for prM (not drawn to scale). Engineered 
mutations are shown together with the corresponding designations. The potential but unused upstream 
NS2B/3
pro
 cleavage site is underlined. The downstream cleavage site of NS2B/3 (black), and cleavage 
sites of SPaseI (blue) and HIV-1 protease (red) are indicated by arrowheads. Numbers at the top refer to 
the amino acid positions within protein C or prM. The transmembrane region is highlighted in blue. 
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Figure 3 
 
 
 
Fig. 3. Analysis of autocatalytic activity of TBEV NS2B/3
pro
. In vitro transcribed RNAs encoding the 
indicated proteins were translated in RRLs in the presence of 
35
S-methionine for 30 min at 30°C. 
Following the addition of unlabelled methionine, samples were incubated for the indicated times in buffer 
containing 50mM NaCl, 50mM Tris/HCl, pH7. Proteins were separated by SDS-PAGE and 
35
S-containing 
proteins detected by fluorography. 
 
 
 
 
 
 
 
 Figure 4 
 
  
Fig.4. Processing of TEBV polyprotein subfragments containing the C and prM proteins by purified 
recombinant NS2B/3
pro
. (A) C-prM. (B) C-2A∆3-prM. In vitro translated substrates were incubated with 
buffer or NS2B/3
pro
 for the indicated times. Proteins were separated by SDS-PAGE and 
35
S-containing 
proteins detected by fluorography. 
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Figure 5 
 
 
 
Fig.5. Effect on proteolytic processing of the synthesis of C-prM subfragments in the presence of 
microsomal membranes (A) C-prM. Translation products were incubated at 30°C for the indicated times. 
(B) C-9L-prM was synthesised in the presence or absence of microsomal membranes and then 
incubated in buffer or with NS2B/3
pro
 at the indicated concentrations and times at 30°C. Proteins were 
separated by SDS-PAGE and 
35
S-containing proteins detected by fluorography.  
 
 
 
 
Figure 6 
 
Fig. 6. Effect of the replacement of the NS2B/3 cleavage site in C-9L-prM with that of HIV-1
pro
 on 
NS2B/3
pro
 processing. C-HIV-9L-prM was translated in the presence (lanes 2 – 5) or absence (lanes 6 to 
8) of microsomal membranes and incubated with buffer or NS2B/3
pro
 at the indicated final concentrations 
and for the indicated times at 30°C. Proteins were separated by SDS-PAGE and 
35
S-containing proteins 
detected by fluorography.  
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Figure 7 
 
Fig. 7. Cleavage at the TBEV C-prM junction by HIV-1
pro
. (A) HIV-1
pro
 cleavage in the absence (lanes 1 
to 3) and presence (lanes 5 to 6) of microsomal membranes. C-9L-prM (upper panel) and C-HIV-9L-prM 
(lower panel) were translated with or without microsomal membranes and incubated with purified HIV-1
pro
 
for 30 min
 
at 30 °C. (B) C-HIV-9L-prM was translated in the absence of microsomal membranes and 
incubated with HIV-1
pro
 in the absence or presence of pepstatin at the indicated concentrations. Proteins 
were separated by SDS-PAGE and 
35
S-containing proteins detected by fluorography. 
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Supplementary Table 1: Sequences of employed oligonucleotides 
 
C-prM-f 5´CCTTACCATGGTAAAGAAGGCCATCCTGAAA  
C-prM-r  5´TTAGGATCCTTATCAAGCGTAAACCGGTGCCAA 3´ 
NS2B-f  5´CCTACCATGGCTAGAAAGATGCAGCTGGTT 3´ 
NS2B-r-3´linker  3´GGATGCGTCAGTCCCGGGAGAAGCACCCATTCTCTTCTTTCTC 3´ 
5´-Linker-NS3-F   5´AGCGGTACTGCACCCGGGGGTAGCGGCGCTTCTGACCTGGTTTTCTCT 3´ 
3´NS3-R-6xHis 5´TTAGGATCCTTATCAGTGATGATGGTGGTGATGTGATGTCCAGCCCGTACC 3´ 
NS3-S135A-f 5´GTGAAAGGAACAGCAGGCAGCCCCATT 3´ 
NS3-S135A-r 5´AATGGGGCTGCCTGCTGTTCCTTTCAC 3´ 
NS3-BglI-f 5´GGCGCTTCAGATCTGGTTTTC 3´ 
NS3-BglI-r 5´GAAAACCAGATCTGAAGCGCC 3’ 
K47A, R50A-f   5´TCGAGGCGGAAGAGGCGATGGGTGGCGGTGGCTCTGGTGGCGGTGGCTCA 3´  
K47A R50A-r  5´GATCTGAGCCACCGCCACCACAGCCACCGCCACCCATCGCCTCCTTCCGCC 3´ 
R50A-f  5´ TCGAGAAAGAAGAGGCGATGGGTGGCGGTGGCTCTGGTGGCGGTGGCTCA 3` 
R50A-r  5´ GATCTGAGCCACCGCCACCAGAGCCACCGCCACCCATCGCCTCCTTCTTC 3` 
TM-9L-f:  5´CTGTTGCTGTTGCTAGCTGCAACGGTGAGGAAAGAAAGG 3´ 
TM-9L-r.  5´CAACAGCAACAGAAGCGTCATCCCCAACAGAGTGATGACCAG 3´ 
prM-∆glyc-f        5´GGTGCGTGTGGAGGCCGGCACCTGTGTGATCC 3´ 
prM-∆glyc-r  5´GGATCACACAGGTGCCGGCCTCCACACCACC 3´ 
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5.1.  Introduction 
 The tick-borne encephalitis (TBE) serocomplex of viruses belongs to the family of 
Flaviviridae, genus Flavivirus. It comprises a number of human pathogens that cause serious 
neurological diseases. The most important member is the tick borne encephalitis virus (TBEV), 
the causative agent of a potentially lethal neuroinfection, TBE (Robertson et al., 2009). In most 
cases, the virus is transmitted to humans through the bite of an infected tick, but it can also be 
acquired by consuming unpasteurised dairy products from viremic livestock (Süss, 2003). 
 In Europe, two vaccines are available: FSME-IMMUN (Baxter, Austria), and Encepur 
(Novartis, Germany), both of which are based on the European subtype (Heinz and Holzmann 
2007). At the moment, there exists no specific treatment for TBE; therapy consists of 
symptomatic and supportive care and management of complications. Thus, a therapeutic agent 
against TBEV would be highly valuable as it could potentially save many lives throughout the 
world. 
 The TBEV is a small, spherical, enveloped virus with a single positive strand RNA 
genome of 10.8 kb. Upon infection, the genome is translated into one single polyprotein which 
is subsequently cleaved into its mature, functional proteins by host cell proteases together with 
the viral protease NS3. The viral cofactor NS2B is essential for the catalytic activity of the NS3 
protease. As the TBEV protease NS2B/3 (NS2B/3pro) is indispensible for the processing of its 
polyprotein and subsequently for virus replication, it is an attractive target for the antiviral 
therapy.  
 The crystal structures of the West Nile virus or the dengue virus NS2B/3pro complex, 
with and without an inhibitor, respectively, have already been solved (Erbel et al., 2006) and 
provided important insight into the mechanism of substrate recognition and activation of the 
NS3pro. The same can be expected from the 3D structure of the physiologically relevant TBEV 
dNS2B/3pro (D´Arcy et al., 2006), which should therefore provide an important impetus to the 
development of a TBEV protease inhibitor. 
 Thus, we set out to optimise expression and purification of the NS2B/3pro complex in 
order to obtain protein of sufficient quality and quantity to allow crystallisation. To obtain well 
diffracting, well-ordered protein single-crystals is the vital aim of protein crystallography and an 
important step towards solving the 3D structure of the NS2B/3pro. 
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5.2. Material and methods 
5.2.1.  Cloning, expression, purification and chemical modification of NS2B/3pro S135A 
 and NS2B/3pro S135A AAA 
5.2.1.1. Cloning 
 Constructs encoding tick-borne encephalitis virus European subtype strain Neudörfl 
(EMBL: U27495) were derived from pBR-TBEV-∆ME-E-EGFP (kind gift of Dr. Petra Schlick). 
Plasmids coding for the inactive NS2B/3pro S135A were constructed in two steps as described 
in Kurz et al., 2012 (manuscript 2) and named pCite-A1-NS2B/3 S135A.  
 For expression in E. Coli, sequences coding for the tethered proteases were cloned 
from pCite-A1-NS2B/3 into the expression vector pET11d by use of NcoI and BamHI. 
 Plasmid pET11d-NS2B/3 S135A K47A E48A E49A (for simplicity subsequently referred 
to as NS2B/3 S135A AAA) was made by site-directed mutagenesis with primers NS2B/3-AAA-f 
(5´GACTGAGCTCGAGGCTGCAGCGAGAATGGGTGC 3´) and NS2B/3-AAA-r (5´GCACCC 
ATTCTC GCTGCAGCCTCGAGCTCAGTC 3´). 
 
5.2.1.2. Expression and purification 
 The plasmids pET 11d-NS2B/3 S135A and pEt11d-NS2B/3 S135A AAA were used for 
high-level, inducible expression of hexa-histidine-tagged (His6) recombinant proteins as 
described in Kurz et al., 2012 (manuscript 2).  
 
5.2.1.3. Lysine methylation (according to Walter et al., 2006) 
 NS2B/3pro S135A was expressed in E.coli BL21 DE3 pLysS and purified using HiTrap 
chelating column and HiLoad TM 26/60 Superdex 75 as stated above. The protein was eluted 
from the latter with buffer containing 50mM HEPES and 250mM NaCl, pH 7.5. Fractions were 
analysed by SDS-PAGE, those containing the protein were pooled. For each ml of protein 
solution 20µl 1M dimethyl-boran complex (freshly prepared in H2O) and 40µl 1M formaldehyde 
were added and left under stirring at 4° C for 2 hours. Then, the same amount of dimethyl-
boran complex and formaldehyde was added again, and left stirring at 4°C for another 2 hours. 
Finally, 10 µl of the 1M dimethyl-boran complex were added per ml protein solution and left 
stirring overnight at 4°C, covered with parafilm. 
The sample was concentrated to 3ml using the Amicon Ultra-4-Centrifugal filter Device and 
applied to the HiLoad TM 26/60 Superdex 75 column preequilibrated with buffer containing 
50mM Tris/HCl, pH 7.5, 100mM NaCl and 5% glycerol. Fractions were analysed via SDS-
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PAGE, pooled and concentrated to 5.25 and 10.5 mg/ml, followed by centrifugation (14000 
rpm, 4°C, 45 min) to remove precipitate. The supernatant was used for crystallisation trials. 
 
5.2.2.  Cloning, expression and purification of fusion protein MBP-NS2B/3 S135A 
5.2.2.1. Cloning 
 Plasmid pet15b-MBP-NS2B/3 was generated as follows: The coding sequence of 
NS2B/3 S135A was cut out of pET NS2B/3 S135A by using primers NS2B/3 NdeI 
(5´CAGTCATATGGCTAGAAAGATGCAGCTG-3´) and NS2B/3-BamHI (5´TGCATGGATCC 
TCACTATGATGTCCAGCCCGTACCCAC 3´). Thereby, a cleavage site for NdeI and BamHI 
was inserted and the C-terminal His6-tag was removed. These enzymes were then used to 
introduce the NS2B/3 S135A coding sequence into vector pET15b-MBP (kind gift of Dr. Gang 
Dong) downstream of the maltose binding protein. The His6-tag at the N-terminus of the MPB 
coding sequence is removable by thrombin cleavage. 
 
5.2.2.2. Expression and purification 
 MBP-NS2B/3pro S135A fusion protein was expressed in E.coli strain BL21 DE3 grown in 
LB medium containing 100mg/ml ampicillin and 35µmol/ml Chloramphenicol at 37°C overnight. 
This culture was diluted 1:100 in fresh LB medium containing ampicillin and incubated at 30°C, 
225 rpm until an OD600 of 0.5 to 0.6 was reached. The expression of the recombinant proteins 
was induced by addition of isopropyl-β-D-thiogalactopyranose (IPTG) to a final concentration of 
0.5 mM. Cultures were incubated overnight at 16°C, and cells were harvested by centrifugation. 
Cell pellets were resuspended in 30 ml lysis buffer containing 50mM Tris-HCl, 200mm NaCl, 
pH 7.5, 5 % glycerol and lysed with a Bandelin Sonoplus sonicator (4 cycles, 40 %, 30 
seconds, 1 cycle, 100 %, 30 seconds) followed by centrifugation at 17,000 rpm for 30 minutes 
at 4°C. The supernatant was loaded onto a 5-ml HiTrap chelating column (GE Healthcare) 
loaded with Ni++ and pre-equilibrated with lysis buffer. The protein was eluted with a linear 
gradient of 10 to 500mM imidazole in lysis buffer. Fractions containing MBP-NS2B/3 protein 
were determined by 12.5 % SDS-PAGE, pooled and diluted to a concentration of 1 mg/ml with 
lysis buffer to reduce the imidazole and NaCl to a final concentration of 60 and 160 mM, 
respectively. The N-terminal His6 tag was removed by incubation overnight with 50 Units/ml 
thrombin. Then, the protein was diluted with lysis buffer to further reduce the imidazole 
concentration, then concentrated to a volume smaller than 13 ml using Amicon Ultra-4 
Centrifugal filter Device 10kDa cut-off (Millipore). To remove the His6 tag, the protein was 
loaded on to a HiLoad TM 26/60 Superdex 75 column (GE Healthcare) equilibrated with buffer 
containing 20mM Tris/HCl, pH 7.4, 100mM NaCl and 5 % glycerol. Fractions were again 
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analysed by SDS-PAGE, protein containing fractions pooled and concentrated to 25, 50 and 66 
mg/ml, respectively. The protein samples were incubated with an equimolar amount of maltose 
for 1 hour at 4°C, followed by centrifugation (60 minutes, 14000 rpm, 4°C). This solution was 
used for crystallisation trials. 
 
5.2.3. Crystallisation techniques 
5.2.3.1. Pre crystallisation test 
 To optimise the protein concentration prior to initial screens a pre-crystallisation test 
(PCT, Hampton research) was performed according to the manufacturers’ instructions. When 
necessary, the protein concentration was adjusted by further concentrating or diluting with 
elution buffer. 
 
5.2.3.2. Crystallisation trials 
 Vapour-diffusion crystallisation experiments were performed using a nano-robot and the 
sitting drop method. In a typical experiment, 0.1 or 0.2 µl protein solution were added to 0.1 µl 
screening solution on 96-well Intelliplates (Robbins Instruments, Sunnyvale, USA), the reservoir 
well contained 70 µl screening solution.  
 The screening solutions used for the experiments were Index, Crystal Screen, Crystal 
Screen Cryo I and II and SaltRX  (Hampton research), the PEGs Suite (NExtal 
Biotechnologies), Wizard I and II (Emerald BioStructures), JCSG+ Suite, PEG Suites (Qiagen) 
and PACT HT96 (Molecular Dimensions Limited). Monitoring of the crystal growth started 
immediately; photos were taken routinely after 12 and 24 hours, and at day 2, 3, 5, 9, 17 and 
31 after setting the drops by using the RIGAKU Crystal Web Site. 
 
5.2.3.3. Streak seeding 
 Crystals were pulverised into crystalline particles by vortexing. The nuclei were streaked 
with a seeding wand onto the surface of a new drop which had been equilibrated overnight at 
196K. 
 
5.3. Results and Discussion 
 In order to be able to determine a molecules´ structure via X-crystallography, 
well‐diffracting crystals are needed. To generate them, a sufficient amount of pure, soluble and 
stable protein is necessary. To this end, the NSB/3pro S135A was overexpressed in E.coli and 
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purified with affinity and size exclusion chromatography (SEC). To maximise the amount of 
soluble protein, several parameters of the expression procedure, including induction and cell 
lysis, had to be optimised  
 
5.3.1. Expression 
5.3.1.1. Optimisation of induction 
 Induction parameters including inducer concentration, period of induction and the cell 
concentration at which the inducer is to be added to the fermentation broth were optimised in 
order to increase the yield of NS2B/3pro S135A. 
5.3.1.1.1. Optimisation of IPTG concentration 
 In order to determine the effect of the inducer concentration on induction efficiency, six 
parallel shake-flask fermentations were performed. The expression was done as described in 
Material and Methods. Plasmid pET 11d NS2B/3 S135A was transformed into competent E.coli 
BL21 DE3 LysS cells and grown in LB medium containing ampicillin and chloramphenicol over 
night at 37°C. The starter culture was 1:10 diluted in LB medium containing selective antibiotics 
and grown at 30°C for around 1 ½ hours until an OD600 of 0.6 was reached. Expression was 
induced with IPTG at a final concentration of 0.0 mM, 0.05 mM, 0.10 mM, 0.25 mM, 0.50 mM 
and 1.0 mM, respectively. After incubation for 4 hours at 30°C, cells were harvested and 
sonicated as described in Materials and Methods. The total protein fraction was analysed via 
SDS-PAGE (Fig. 1).  
 
 
Figure 1. Optimisation of IPTG concentration. Protein expression was performed as described in 
detail in Material and Methods. Protein expression was induced with various IPTG concentrations 
between 0.05 and 1 mM. Aliquots were taken 4 hours post induction, sonicated, centrifuged and 
analysed via SDS-PAGE. M indicates the Precision Plus Protein All Blue Standards (BioRad) Marker. 
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 The protein expression reached a maximum at an IPTG concentration of 0.1 mM. A 
further increase in the IPTG concentration did not improve protein production. Thus, an IPTG 
concentration of 0.1 mM was used in all further experiments. 
5.3.1.1.2. Optimisation of starting time and period of induction 
 In order to determine the optimal starting time of induction, six shake-flask fermentations 
were performed in parallel. Each culture was induced at different phases of growth, namely at 
absorbance values of 0.6 and 0.9 at 600 nm. Following the addition of 0.1 mM IPTG to each of 
the culture media, the incubation was continued over a 4, 5 or 6-hour period, and protease 
expression was determined in cell extracts after sonication.  
 As shown in figure 2, a maximal yield was obtained with an induction at an OD600 of 0.6 
and harvest of cells after 4 hours. 
 
 
Figure 2. Optimisation of optimal starting time and period of induction. The protein expression was 
performed as described in detail in Material and Methods. The starter culture was 1:10 diluted in LB 
medium with selective antibiotics and grown at 30°C until an OD600 of 0.6 and 0.9 was reached. Protein 
expression in both cultures was induced with the optimised IPTG concentration of 0.1 mM. Aliquots were 
taken 4, 5 and 6 hours post induction. Then, cells were sonicated, centrifuged and analysed via SDS-
PAGE. 
 
5.3.1.2. Optimisation of cell lysis: Sonication vs. French Press 
 For the extraction of soluble protein from bacteria various methods are available; many 
of these need specialised, expenisve equipment. We compared two simple methods for cell 
disruption, namely French pressing and sonication. 
 NS2B/3pro S135A was expressed under optimised conditions as described in Material 
and Methods. 2 ml of induced and uninduced cells were sonicated on ice (4 times, 30 seconds, 
20 %). In a second setup, induced cells only were applied to one or two cycles of French Press. 
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Soluble and insoluble fractions were separated by centrifugation. The SDS-PAGE results are 
shown in figure 3.  
 
 
Figure 3. Efficiency of cell lysis. Cells were lysed by (A) sonication or (B) French press. Total (T), 
insoluble (I) and soluble (S) fractions were analysed via SDS PAGE; 5 µl of the samples were loaded on 
a 15% SDS PAGE; M = Marker 
 
 The method of cell lysis did not have a major influence on the amount of soluble protein 
produced. Thus, sonication was used in all further protein preparation procedures, as it is less 
labour and time intensive. 
5.3.2. Purification 
5.3.2.1. Affinity chromatography 
 The purification of the NS2B3/3pro S135A is described in detail in the Material and 
Methods section. The NS2B3pro S135A carries a His6-tag at the C-terminus, which was used for 
purification via affinity chromatography. The soluble fraction of the cell lysate was loaded onto 
the Hi-Trap column pre-equilibrated with Nickel. The protein was eluted with a linear gradient of 
imidazole in lysis buffer.  
 5 µl of each fraction of the second peak A8 to A12 were analysed via SDS-PAGE (Fig. 
4, picture inlay). The most prominent bands run with a molecular weight slightly above 25 kDa. 
This is in good agreement with the calculated molecular weight of the NS2B/3pro S135A of 28 
kDa, indicating that the protease was already highly pure and concentrated after the first 
purification step.  
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Figure 4. Example of an affinity chromatography profile. The gel picture shows the eluted fractions 
A8 to A12 corresponding to the second peak in affinity chromatogram). 
 
5.3.2.2 Size exclusion chromatography (SEC) 
 Fractions A8 to A12 from the affinity chromatography were pooled, concentrated by 
centrifugation and applied to SEC. 
 Peaks A and C were analysed via SDS-PAGE. Interestingly, the molecular weight of the 
protein in both fractions was the same. Western blot analysis showed that both peaks held 
NS2B/3pro (data not shown). We assume that the protein eluted with the first peak is aggregated 
protein. Thus, eluat from peak A was not used for further experiments. 
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Figure 5. Example of a size exclusion chromatography profile and SDS-PAGE after gel filtration. 
(A) SEC profile, (B) and (C) SDS-PAGE of fractions of peak A and C, respectively (2,5 µl/lane). (D) The 
fraction of both peaks A and C were concentrated separately and analysed by SDS-PAGE (0.5 µl,         
11 mg/ml) 
 
5.3.3. Quality analysis 
 Homogeneity, both chemical and conformational, stability and solubility of a biological 
macromolecule are key factors that have a strong effect on the probability of obtaining crystals. 
Thus, these parameters have to be tested. 
5.3.3.1. Dynamic light scattering (DLS) 
 Dynamic light scattering is applied in protein crystallography to obtain information about 
a protein in solution. Hereby, the proteins hydrodynamic radius is determined, as well as 
information about the oligomeric state of the protein sample. The extent of size distribution is a 
parameter for the polydispersity of the sample and correlates with protein crystallisation 
success. Thus, DLS represents a simple and non-invasive screening technique for evaluating 
the crystallisability of protein solutions.  
 NS2B/3pro S135A from the initial purification at a concentration of 11 mg/ml in Tris/HCl, 
pH7, 50mM NaCl and 5 % was analysed using DLS to determine its suitability for crystallisation 
 66 Manuscript 3 
as described by Ferre-D’Amare Burley (1994) and Zulauf & D’Arcy (1992). The protein was 
filtered through 0.22 µm centrifugal units prior to analysis, all measurements were made at 
296K. 
 The protein preparation was found to be monodisperse to a very high degree when 
examined by DLS. 
 
 
 
Figure 6. Size distribution profiles from the DLS. The results indicate a monodisperse preparation for 
the concentrated sample peak C of the SEC profile. 
 
5.3.3.2. Thermofluor 
 In order to determine whether the NS2B/3pro S135A is folded and which buffer could 
help to improve stability and folding of the protein, a Thermofluor measurement was performed. 
 The method exploits the fact that it is possible to distinguish between folded and 
unfolded proteins through exposure to a hydrophobic fluorophore which is quenched in 
aqueous solution. Thus, as long as the protein is properly folded and the hydrophobic areas are 
buried in the interior of the protein, no fluorescence signal is observed. However, with 
increasing temperature, the protein starts to unfold, thereby exposing its internal hydrophobic 
domains. These bind the fluorophore, as a consequence, the quenching effect of the water is 
abolished. Thus, this interaction gives rise to a fluorescence signal which is a function of 
temperature. In this way, the melting temperature Tm of the protein can be determined. 
Conditions which cause an increase in the melting temperature of the protein stabilise it. 
Furthermore, it is assumed that a more stable protein is more prone to crystallise (Ericsson et 
al., 2006) 
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 The Thermofluor experiment was performed on a 96-well real‐time PCR machine 
(BioRad) as done by Nettleship et al., 2008 and Lo et al., 2006. This way, 96 different buffer 
conditions could be tested simultaneously.  
 
Figure 7. Melting curves of NS2B/3pro S135A in different buffer systems. A temperature gradient 
was applied, starting from 4 C and increasing to 95 C, measuring the fluorescence signal every 0.5 min. 
SYPRO® Orange (Invitrogen) was used as fluorophore, the absorption was measured at a wavelength of 
600 nm. A sigmoidal curve (thermogram) was obtained by plotting the fluorescence intensity against the 
temperature.  
 
 The Thermofluor experiments showed that the protein was correctly folded in almost 
any buffer system tested. Exceptionally high melting temperatures were determined in buffer 
containing 2-(N-morpholino)ethanesulfonic acid (MES, red curve, peak at 56°C), pH 5.8 and in 
Tris/HCl buffer (violet curve, peak at 54°C), pH 7.5, respectively.  
 The latter one is the buffer system with which the protein was initially eluted from the 
SEC column. To test whether the MES buffer could further stabilise the NS2B/3pro S135A and 
thus favour its crystallisation, we expressed and purified it again as described in Materials and 
Methods. This time, the sample was eluted in buffer containing 50 mM MES, 50 mM NaCl and 
5% glycerol and concentrated to 10, 20 and 30 mg/ml. As before, the samples were analysed 
by SDS-PAGE and DLS and proven to be of sufficient purity and homogeneity for crystallisation 
(data not shown). 
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5.3.4. Crystallisation 
 At the beginning of the crystallisation process, purified, highly concentrated protein is 
diluted in an aqueous solution with a precipitant concentration lower than that needed for 
crystallisation. In the curse of slow evaporation of the solvent, both protein and precipitate 
concentration are enhanced; thereby, precipitating conditions are generated which allow 
crystallisation to occur. These conditions remain stable until crystal growth terminates. Once 
suitable protein crystals become available, X-ray diffraction data can be collected. 
 The crystallisation experiment starts by testing a wide range of screening conditions to 
find the precipitant that favours crystallisation. Commercially available crystallisation suites 
allow a combination of various chemical conditions to be tested in a systematic manner.  
 
5.3.4.1. NS2B3pro S135A 
5.3.4.1.1. Buffer systems 
 The protein solutions in Tris and MES buffer were both set up for crystallisation trials as 
described in Material and Methods. For the protein solutions either three (Tris) or two (MES) 
different protein concentrations were used in 8 different commercially available screening kits. 
Each of these kits tests 96 different buffer solutions. They were used at two different protein to 
precipitant ratios (1:1 and 2:1) and at 277K and 296K, respectively. This makes a total of more 
than 7500 conditions tested. 
 Unfortunately, no crystal or crystalline material was found in any of the tested 
conditions. 
 
5.3.4.1.2 Surface engineering 
 Molecular flexibility has a negative effect on the formation of a highly ordered crystal 
lattice. Such flexibility arises from motions of different domains of the polypeptide chain or from 
small movement due to solvent exposed, mobile amino acid side chains (Walter et al, 2006).  
 One possibility to eliminate this latter problem is to selectively substitute these residues 
with smaller, hydrophobic ones (Lawson et al., 1991). Such surface entropy reduction (SER) 
mutagenesis is an established technique. Still, as it requires the modification of expression 
plasmids, it remains time-intensive and laborious. 
 As an alternative, it is possible to reduce the surface entropy by chemically modifying 
the proteins surface (Rayment et al., 1993). The most frequently used technique is the 
reductive methylation of free amino groups. Hereby, primary amines, like the N-terminus and 
lysine residues, are converted into tertiary amines. In this way, repulsive charges of exposed 
side chains are reduced.  
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Lysine Methylation 
 Lysine and glutamic acid residues on the surface of proteins have long side chains that 
are mobile. Addition of methyl groups immobilises them and might therefore improve protein 
crystallisability.  
 NS2B/3pro S135A was expressed, purified and its lysines methylated as described in 
Materials and Methods except that the final elution step was done with buffer containing 50 mM 
Tris/HCl, pH 7.5, 100 mM NaCl and 5% glycerol. Fractions were analysed via SDS-PAGE, 
protease containing fractions were pooled and concentrated to 5.25 and 10.5 mg/ml. Finally, 
the sample was centrifuged at 14000 rpm, 4°C for 45 minutes, to remove precipitate. The 
supernatant was highly pure as confirmed by SDS-PAGE (data not shown) and was thus used 
for crystallisation trials. 
 Even though more than 1000 screening conditions were tested with above mentioned 
screening kits, again no crystal growth could be observed. 
 
Surface Entropy Reduction mutagenesis 
 A study done by Cooper et al., 2007 strongly supports the notion that substitution of 
high-entropy surface residues with ones that favour intermolecular contacts might facilitate the 
production of high quality crystals for structural analysis.  
 To find appropriate residues at the surface of the NS2B/3 protein, the online program 
UCLA MBI — SERp Server was used (http://nihserver.mbi.ucla.edu/SER/). Good candidates 
for mutation typically have clusters scores of 3.0 and above. 
Table 1: Results of the SERp online tool that identifies sites that are most suitable for mutation designed 
to enhance crystallisability by a Surface Entropy Reduction approach. 
Cluster #1:   Residues 47 - 49: EKEE  
  
SERp Score: 7.39  
 
 
 
 
Cluster #2:   Residues 148 - 150: EEKWKGETVQVHA  
  
SERp Score: 7.12  
 
 
 
 
Cluster #3:   Residues 230 - 233: AQGEAEK  
  
SERp Score: 6.87   
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 As suggested by the program, residues K47, E48 and E 49 were mutated to alanine. 
Expression and purification were done as described previously and yielded again high amounts 
of pure, stable protein which was used for crystallisation assays. 
 Although more than thousand conditions for the protein with reduced surface entropy 
were tested, again no crystal or crystalline material was found. 
 
5.3.4.2. NS2B/3pro S135A with a large-affinity tag (maltose binding protein, MBP) 
 As already more than 10.000 conditions had been tested, we changed the crystallisation 
strategy and made some major changes to the protein. 
 In order to improve expression, solubility and folding of a protein, or to facilitate protein 
purification via affinity chromatography, it is a well-known technique to bind the protein of 
interest to a large-affinity tag, such as maltose-binding protein (MBP) or glutathione-S-
transferase (GST) (Beckwith et al., 2000). As a side effect, these fusion tags often generate a 
conformational diversity, which might be detrimental to crystal growth. Therefore, large fusion 
tags are often removed prior to crystallisation by a potentially problematic cleavage step (Smyth 
et al., 2003). 
 However, it is possible to avoid such cleavages and keep the tag for the crystallisation 
trials. This might have, beside the above mentioned disadvantages, several advantages: Such 
fusion proteins can generate scaffolds which stabilise the protein of interest, thereby favouring 
crystallisation. In this way, the 3D structure of the human T cell leukaemia virus I gp21 
ectodomain (Kobe et al., 1999), the MATa2 homeodomain (Ke et al., 2003) and the SarR 
protein (Liu et al., 2001) could be solved. In these structures, MBP is responsible for most of 
the crystal contacts and consequently for the formation of the crystal (Derewenda, 2004).  
 
5.3.4.2.1. Sample preparation and crystallisation 
 Plasmid pet15b-MBP-NS2B/3 was generated as described in detail in Material and 
Methods. The initial expression protocol had to be changed, as the MPB-NS2B/3pro S135A was 
predominately found in the insoluble fraction when expressed in E.coli BL21 DE3 pLysS (data 
not shown). The protein was soluble when we expressed it in E.coli BL21 DE3 and in the 
absence of chloramphenicol. Thus, this bacterial strain was used for further expression 
procedures. The purification was done as described before. In an additional step, the N-
terminal His6 tag was removed by thrombin cleavage, followed by another SEC. Finally, the 
protein samples were concentrated to 25, 50 and 66 mg/ml, respectively. All proteins solutions 
were then supplemented with an equimolar amount of maltose to stabilise the MBP. After 
centrifugation to remove precipitation, all samples were analysed via SDS-PAGE (Fig. 8). The 
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fusion protein has a calculated molecular weight of 68 kDa. Although very minor degradation of 
the fusion protein can be detected when 0.5 µl were applied, all samples were used for 
crystallisation trials at 277K and 296K. Again, several commercially available precipitant kits 
were used, including the Crystal suite, Wizard I and II. 
 
 
Figure 8. Analysis of concentrated samples of MBP-NS2B/3
pro
 S135A. 0.1, 0.2, 0.3 and 0.5 µl of the 
final sample (66 mg/ml) were analysed via SDS-PAGE.  
 
 Here, potentially crystalline material was found between day 17 and 31 in the Crystal 
Screen (Hampton research) in condition number 32 (2 M ammonium sulphate), at a precipitate 
to protein ratio of 1:2 (i.e. 0.666 M ammonium sulphate). In contrast, at a precipitate to protein 
ratio of 1:1 (i.e. 1 M ammonium sulphate), oils were found already 12 hours after the drops 
were set (Figure 9).  
 
 72 Manuscript 3 
 
Figure 9. Oils (left panel) and crystals (right panel) of the MBP-NS2B/3pro complex. Protein 
solutions at a concentration (stated on the left) of 66 mg/ml (A), 50 mg/ml (B) and 25 mg/ml (C) were 
mixed with precipitant solution (2 M ammonium sulphate) either 1:1 (i.e. final conc. ammonium sulphate: 
1M; left panel) or 2:1 (i.e. final conc. ammonium sulphate: 666 mM, right panel). Crystals were formed to 
an extent proportional to the protein concentration (compare right panels A with B and C).  
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5.3.4.2.2. Characterisation of the crystals – is it salt or protein? 
 At a concentration of 666 mM ammonium sulphate (Fig. 9, right panel), the extent of 
crystalline material varied in a relation directly proportional to the amount of protein used. This 
indicates that these are indeed protein crystals. However, as salt crystals form very easily in 
protein drops, further characterisation of the crystals was needed. 
 Proteins show epifluorescence at 340 nm when exposed to UV light. Thus, we 
investigated the crystals with a microscope equipped with a UV light source. The crystal 
showed epifluorescence (data not shown), further confirming the protein character of the 
crystals. 
 As the crystals were too fragile to be mounted, a further characterisation via SDS-PAGE 
or western blot could not be performed. Thus, it is possible that the crystals are composed of 
degraded protein instead of full-length MBP-NS2B/3pro S135A.  
 However, several facts speak against this possibility. First, the MBP as a single protein 
crystallised in the presence of polyethylenglycol but not in 2M ammonium sulphate (Souza et 
al., 2008), the condition in which we observed crystals. Second, the MBP was stable during 
prior crystallisation experiments (Quiocho et al., 1997; Souza et al., 2008). The same is true for 
the NS2B/3pro S135A, which did not show any degradation during prior stability experiments 
(data not shown) and did also not crystallise in 2 M ammonium sulphate. Consequently, we can 
exclude that what we found are crystals of the single proteins of MBP or NS2B/3pro S135A, nor 
of any of their degradation products. Thus, we conclude that we finally succeeded in 
crystallising the full length MBP-NS2B/3 S135A.  
 
5.3.4.2.3. Optimisation of crystal growth 
 Unfortunately, the optimal conditions for nucleation of crystals do not favour their 
subsequent growth (Bergfors et al., 2003). Spontaneous nucleation needs an elevated degree 
of supersaturation whereas the growth of diffraction quality crystals occurs at lower levels. 
Thus, the ideal experiment separates nucleation from growth, thereby fulfilling the different 
requirements of both processes. This can be achieved by seeding previously nucleated crystals 
into new drops, preequilibrated at lower levels of supersaturation. 
 Thus, to improve the size and quality of the crystals, streak seeding was performed as 
described in Materials and Methods. Again, crystals could be observed at day 19, indicating 
that crystal growth is reproducible (data not shown). Nevertheless, with this approach, the size 
and quality of the crystals could not be improved. Thus, further optimisation is needed. 
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5.4. Conclusion 
 Crystallisation properties of proteins differ greatly and are difficult to predict. Some 
proteins crystallise in numerous conditions, even though they are only rudimentarily purified. 
Crystallisability of others is very limited and restricted to a few conditions even after intensive 
purification. For the latter, it may prove difficult to identify initial hits. This was the case with the 
NS2B/3pro. Although SDS-PAGE, DLS and Thermofluor results confirmed the purity and correct 
folding of the protein, no crystalline material could be detected in more than 10.000 conditions 
tested. Neither surface entropy reduction by lysine methylation nor mutagenesis nor the use of 
several different buffer systems, temperatures and protein concentrations led to any success. 
One possible reason might be that NS2B and NS3 are connected by a flexible linker, which 
could be detrimental to crystallisation. This theory is supported by the fact that fusing the 
protease to the large MBP finally led to the growth of crystals. MBP is known to be responsible 
for most of the crystal contacts in many of the successfully crystallised fusion proteins 
(Derewenda et al., 2004), and might therefore minimise the inhibitory effect of the linker. 
 As a result, after more than 20,000 conditions tested, we succeeded in reproducibly 
growing protein crystals of the fusion protein MBP-NS2B/3pro S135A. Although the crystals are 
of insufficient quality and size, these data are the basis for further optimisation and an important 
step toward structure determination of the functional NS2B/3pro S135A complex. 
 Once suitable protein crystals are available, X-ray diffraction data can be collected. 
Each structure determination by X-ray crystallography includes the calculation of the phases of 
the diffraction data. As the structure of the MBP has already been determined, molecular 
replacement can be directly applied to the native dataset (Smyth et al., 2003). Therefore, the 
crystallographic phase problem can be solved by using the MBP as a search model. This 
should facilitate and accelerate future structure determination. 
 Another possibility to determine the 3D structure of a protein at atomic resolution is 
nuclear magnetic resonance (NMR) spectroscopy where the data is recorded while the protein 
is in solution. Considering that many proteins perform their physiological functions in their 
soluble form, knowledge of the molecular structures in solution is highly relevant. Nevertheless, 
NMR spectroscopy is restricted to proteins of relatively low molecular weight (< 30 kDa). 
Furthermore, results are less clear than those obtained with X-ray crystallography.  
 As the NS2B/3pro S135A has a molecular weight of 28 kDa, it is a possible candidate for 
structure determination via NMR spectroscopy. First, we had to examine whether the protease 
can be expressed in bacteria that are grown in M9 minimal medium, containing all the salts and 
trace elements needed by the bacteria, but with glucose and ammonium chloride as the only 
carbon and nitrogen source, respectively. These elements can be isotopically labelled; they 
become incorporated into the protein during expression. We tried to express the NS2B/3pro 
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S135A in minimal medium and succeeded (data not shown), thus fulfilling the first prerequisite 
for future NMR spectroscopy analysis. 
 As NMR data could further increase the knowledge generated from X-ray 
crystallography data, determining the structure of the NS2B/3pro S135A by NMR spectroscopy 
might be another goal worth pursuing. 
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6. GLOBAL DISCUSSION 
 Proteolysis by viral enzymes plays a fundamental role in the life cycle of many viruses 
(Krausslich and Wimmer 1988; Hellen et al., 1989); this makes them an interesting target for 
the antiviral therapy. Several protease inhibitors have already been developed; for instance, 
inhibitors that target the HIV protease are the basis of the anti-retroviral therapy (Piacenti et al., 
2006). Infections against which specific antiviral therapeutics are needed include those of the 
hepatitis C virus (Lamarre et al., 2003), West Nile virus as well as tick-borne encephalitis virus 
(TBEV) (Mansfield et al., 2009). The same is true for animal pathogens, such as the foot and 
mouth disease virus (FMDV), which infects cloven-hoofed animals and causes considerable 
economic losses in livestock production (Grubman and Baxt, 2004). 
 Although extensive knowledge on proteolysis requirements has been generated 
throughout the last decades, viral proteolysis is still a cryptic and highly complex process. 
Cleavage sites are often insufficiently defined, influenced by neighbouring residues or by their 
structural context. This makes cleavage efficiencies unpredictable. Furthermore, the 
development of resistance to inhibitors due to the high mutation rate of the viral RNA 
polymerase is a constant problem. To overcome these obstacles, detailed information on 
substrate specificity and resistance to inhibitors is needed. Therefore, novel systems are 
required that allow the generation of a large number of escape mutants in a random manner 
and to analyse them systematically. 
 Thus, the overall objective of this work was to develop sensitive systems that allow us to 
examine the properties of various viral proteases in general and of the TBEV protease in 
particular. We used the TBEV itself as such a tool for several reasons. Firstly, due to its error 
prone RNA polymerase, TBEV produces a large number of mutants with approximately one 
error per synthesised genome. From this pool of mutants, infectious TBEV particles or single 
round infectious VLPs can be selected over the non-infectious ones by simply measuring their 
infectivity. Thirdly, by investigating the infectivity, we determine a parameter which is directly 
relevant for viral pathogenesis. The presence of suboptimal substrates or protease inhibitors 
should provoke the generation of TBEV escape mutants. Examination of the nature of the 
mutations will give important information about the rate at which resistance occurs and shed 
light onto the responsible mechanisms. In this way, information about the qualification of an 
inhibitor in clinical applications is generated.  
 To make this system usable for other viral proteases, it is necessary to inactivate 
NS2B/3pro cleavage at the C-prM junction by introducing a cleavage site from another protease, 
thereby preventing the production of viral particles. This then allows the reactivation of the 
TBEV through the expression of a corresponding heterologous protease. In this way, the 
described above system can be used to examine the properties of the heterologous protease. 
 78 Global Discussion 
Furthermore, it allows the analysis of the consequences of the altered processing for C and 
prM properties and their relevance for the TBEV life cycle. 
 As described in detail in manuscript 1 (Schrauf and Kurz et al., 2012), we modified the 
genome of TBEV in such a way that the production of infectious virions became dependent on 
the activity of the FMDV 3C protease (3Cpro) instead of the TBEV protease (NS2B/3pro). Virion 
production was achieved by providing an optimised FMDV 3Cpro cleavage site at the C-prM 
junction and the protease itself either in cis or in trans from a TBEV replicon, with the trans 
complementation system being more efficient and stable. In the monocystronic system, viruses 
regained a viable NS2B/3 cleavage site in the absence of an active 3Cpro. Analysis of the 
revertants revealed a previously undetected role of the C-terminus of protein C and the 
necessity of positive charges for efficient budding of the NC. Finally, the results suggest that 
the re-establishment of a NS2B/3pro cleavage in the same region is beneficial for viral spread 
over a co-translational separation of C and prM, as described by Schrauf et al., 2009. This 
underscores the importance of the concerted progression of NS2B/3pro and SPase1 cleavage, 
presumably because in this way, protein C is kept in close proximity to the ER membrane, 
thereby promoting efficient budding of the nucleocapsid. 
 Taken together, this assay was used to investigate principal molecular mechanisms of 
the TBEV itself as well as characteristics of the NS2B/3 and FMDV 3C protease cleavage. 
Furthermore, it provides the basis for future inhibitor studies. The conceptional basis of this 
system, i.e. the use the inherent replicative infidelity of the viral polymerase to introduce 
random mutations into a heterologous gene of interest, is, to our knowledge, unique, and 
should find broad application in various fields of virology. Finally, by using the replicon system, 
problems usually associated with infectious material, are avoided. This simplifies handling and 
manipulation of all pathogens; however, it is of special interest for BSL-3 and BSL-4 viruses.  
 To generate mutants of TBEV with cleavage sites for heterologous proteases but not 
the NS2B/3pro, it is important to have a profound understanding of the cleavage mechanism and 
substrate specificity of the NS2B/3pro. Therefore, we established a biochemical assay to 
investigate in vitro the cleavage of the NS2B/3pro. Furthermore, this assay allows us to test the 
suitability of diverse cleavage sites to be processed by various heterologous proteases.  
We expressed both active and inactive variants of NS2B/3pro of TBEV as a His-tagged protein 
in E.coli. The NS2B/3 fusion proteins were expressed in a soluble form in bacteria and could be 
purified to homogeneity. As substrate, we expressed a fragment of TBEV coding for the C and 
prM region in rabbit reticulocyte lysates. Specific cleavage at the C-prM junction required the 
presence of microsomal membranes, which in turn required a lengthening of the 
transmembrane segment at the C-prM junction to inhibit incorrect processing by the SPaseI. 
Substitution of the NS2B/3pro cleavage motif at the C-prM junction by one of the HIV-1pro 
allowed us to examine cleavage by the HIV-1pro and revealed the presence of a potential 
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second HIV-1pro cleavage site in the prM coding sequence. This second cleavage was observed 
in the absence and presence of membranes, indicating that the protein was inserted into the 
membrane inside-out. We could pin this misorientation down to the presence of the HIV-1pro 
cleavage site in the C-terminal region of protein C. Furthermore, we conclude that this 
misorientation is the cause for our failure to generate a TBEV dependent on cleavage of the 
HIV-1pro as we report in manuscript 1 for the FMDV 3Cpro (Schrauf and Kurz et al., 2012). 
However, the biochemical assay will allow us to modify the cleavage site of HIV-1pro in order to 
prevent the cryptic cleavage as well as incorrect membrane insertion of the protein. As a result, 
the assay should promote the construction of a TBEV that is dependent on the activity of the 
HIV-1pro.  
 As proteolytic cleavages are highly dependent on the structural context of their 
substrate, especially when membrane proteins are involved, it is important to examine their 
characteristics in a natural environment. However, biochemical assays provide some 
advantages over cell based ones. First, they present a fast and safe method to investigate 
characteristics of proteases without the need of special laboratory equipment or infectious 
material. Secondly, in contrast to cell based assays, they offer the opportunity to study isolated 
mechanisms without being influenced by associated processes; i.e. the system described in 
detail in manuscript 2 (Kurz et al., 2012, submitted), may provide a model for examining the 
orientation of the transmembrane anchor of the TBEV protein C as well as the requirements for 
correct SPaseI processing. Furthermore, due to the inherent glycosylation activity of the 
ribosomal membranes, the influence of glycosylation of protein M on NS2B/3pro processing can 
be studied. In this way, this assay is a valuable tool for itself. However, it is also an essential 
supplement for the above described cell based assay.  
 Finally, in order to promote the design of an inhibitor for the TBEV NS2B/3pro, we 
attempted to solve its 3D structure by X-ray crystallography. Structures of the proteases of 
other flaviviruses (e.g. WNV and DENV) are already available. However, our results (discussed 
in manuscript 2) indicate a fundamental difference in the processing of TBEV and WNV 
polyprotein, as Yamshchikov and Compans, 1994, who examined the cleavage of WNV C-prM 
by WNV NS2B/3pro, did not observe SPaseI cleavage when C-prM was translated in the 
presence of microsomal membranes and when NS2B/3pro was excluded from the reaction. This 
is in contrast to our results and underlines, together with a sequence identity of less than 50 % 
of the two viral proteases, the need to solve the structure of the TBEV NS2B/3pro.  
 Therefore, we attempted to obtain crystals with various preparations of the inactive 
NS2B/3pro by using the sitting drop method. After intensive screening at 4°C and 20°C of a 
huge variety of conditions, we did not succeed in obtaining crystals of the protease. In order to 
minimise repulsive charges of the protein, thereby enhancing the chance of getting crystals, 
lysine methylation as well as surface entropy reduction mutagenesis was performed. Both 
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attempts were not successful. Only when we fused the NS2B/3 coding sequence to that of the 
maltose binding protein (MBP), thereby minimising a potential inhibitory impact of the flexible 
linker, did we obtain crystals in one of the conditions tested. Crystallisation occurred in a protein 
concentration dependent manner. Crystals were of suboptimal quality and size; however, they 
could be grown reproducibly. Thus, this work is the basis for further crystal optimisation and an 
important step toward structure determination.  
 Taken together, the results of this thesis extend the knowledge and understanding of 
basic molecular mechanisms of the TBEV and further clarify cleavage requirements of the 
proteases of TBEV, FMDV and HIV. The concept of the established assays allows the study of 
various aspects of viral pathogenesis and development of resistance to inhibitors. Therefore, 
this work provides the basis for analysing structure function relationships of viral proteases and 
should therefore facilitate future drug design.  
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9. Poem of the day          
 
 
Mutations 
Mutations, 
Mutations, 
Mutations.      Carla 
 
 
Thinking 
I stink... when I think…    Carla 
 
 
Breadcrumbs 
They are nice.     Carla 
 
 
Breadcrumbs 
They are.      Tina 
 
 
Yoghurt 
It is gone (like the protein).    Tina 
 
 
Nobel Sorrow 
One week too soon.  
One hour too late.     David 
 
 
34 
34… very young 
Nevertheless, applying for a leader position… 
Enviousness.      David 
 
 
Exhaustion 
Inoculation of  
two colonies…     David and Carla 
 
 
Communication… 
It’s difficult.      Carla 
 
